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Abstract:  
Two new series of symmetric acyclic nucleoside bisphosphonates (ANbPs) have been 
synthesised as potential inhibitors of the Plasmodium falciparum (Pf) and vivax (Pv) 6-
oxopurine phosphoribosyltransferases. The structural variability between these symmetric 
ANbPs lies in the number of atoms in the two acyclic linkers connecting the N9 atom of the 
purine base to each of two phosphonate groups and the branching point of the acyclic moiety 
relative to the purine base, which occurs at either the alpha or beta positions. Within each 
series, six different 6-oxopurine bases have been attached. In general, the ANbPs with either 
guanine or hypoxanthine have lower Ki values than for those containing either the 8-bromo or 
7-deaza 6-oxopurine bases. The lowest Ki values obtained for the two parasite enzymes were 
0.1 µM (Pf) and 0.2 µM (Pv) for this series of compounds. Two phosphoramidate prodrugs of 
these inhibitors exhibited antimalarial activity against Pf in infected erythrocyte cell culture 
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with IC50 values of 0.8 and 1.5 µM.  These two compounds exhibited low cytotoxicity in 
human A549 cells having CC50 values of >300 µM resulting in an excellent selectivity index.  
 
1. Introduction 
Despite concerted efforts to eradicate malaria, it still remains as one most serious 
infectious diseases on the planet today, with 300-500 million cases reported annually.1 Many 
of the currently available antimalarial drugs has been discovered serendipitously by screening 
of a large number of compounds or they are based on natural products used in traditional 
medicine.2,3,4 However, the development of resistance to present drugs has become a serious 
problem. Therefore, to control the spread of malaria requires new drug targets to be identified 
and new drug leads to be developed into pharmaceuticals.5  
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Figure 1. A) Reaction catalysed by HG[X]PRT. R = H (hypoxanthine), R = NH2 
(guanine), R = OH (xanthine). B) General structure of the acyclic bisphosphonates (ANbPs).  
Our approach to antimalarial drug discovery is based on the fact that the two principle 
protozoan parasites causing human malaria, Plasmodium falciparum (Pf) and Plasmodium 
vivax (Pv), are unable to synthesize the purine ring de novo and depend on the active transport 
of these bases from their host cell for the synthesis of the purine nucleoside monophosphates 
essential for DNA/RNA production.6,7,8,9 These purine nucleoside monophosphates, GMP, 
IMP and XMP, are unable to cross the plasmodial membrane and therefore need to be 
synthesised within Pf and Pv by hypoxanthine-guanine-[xanthine] phosphoribosyltransferase 
(HG[X]PRT) (Fig. 1A). In addition, for Pf and Pv, the only pathway to synthesise AMP is 
from IMP.6,10 HG[X]PRT is, therefore, the key enzyme in the synthesis of both the 6-
oxopurine and 6-aminopurine nucleoside monophosphates. Thus, inhibition of HG[X]PRT 
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activity should prevent nucleic acid synthesis. A number of studies have confirmed that 
HG[X]PRT inhibitors prevent the growth of Pf after it has invaded the red blood cells.8,11  
The acyclic nucleoside bisphosphonates (ANbPs) are a group of flexible, metabolically and 
chemically stable compounds whose chemical structure is based on the substrates/products of 
the reaction (Fig. 2B). These compounds were derived from a basic scaffold of acyclic 
nucleoside phosphonates (ANPs), which are nucleotide analogues developed as effective 
antiviral agents.12 In general, ANPs have ability to target various metabolic pathways  where 
they exhibit a wide range of biological activities, e.g. antibacterial, immunomodulatory and 
antineoplastic13,14,15,16,17 and can serve as monomers for oligonucleotide synthesis.18 
 
Figure 2.  Previously synthesised symmetrical ANbP-based HG[X]PRTs inhibitors.19  
Nucleoside phosphonates bearing guanine or hypoxanthine as the nucleobase are effective 
inhibitors of Pf HGXPRT and Pv HGPRT. They also inhibit the bacterial 6-oxopurine 
PRTases from Mycobacterium tuberculosis,20 Escherichia coli,21,22 and the HGPRT found in 
the parasite Trypanosoma brucei23. A variety of different structural analogues of these 
phosphonate inhibitors have been synthesised, including the single chain ANPs, the ANbPs, 
the aza-ANPs, the pyrrolidine nucleoside phosphonates, the pyrrolidine nucleoside 
bisphosphonates and the acylic immucillin phosphonates.24,25,26,27,28 The crystal structures of 
the single chain ANPs in complex with HG[X]PRT [20] suggested that the attachment of a 
second phosphonate group to the basic ANP scaffold may allow a single molecule to occupy 
three critical binding pockets in the active site. These include the sites for the purine base, the 
5′-phosphate group and, possibly, the pyrophosphate product (Fig. 1A). The inhibition of 
human HGPRT, Pf HGXPRT and Pv HGPRT by four ANbPs has previously been reported19 
and the chemical structures of three of these are shown in Fig. 2. The most potent inhibitor is 
1a with a Ki value of 70 nM for Pf HGXPRT though the Ki for Pv HGPRT is 10-times higher, 
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600 nM.19 In comparison, compound 2 is a weaker inhibitor with a Ki value of 2 µM for Pf 
HGXPRT and a Ki for Pv HGPRT of 18 µM. 
Herein, we report the synthesis of two new series of the ANbPs based on the structures 
presented in Fig. 2 together with an evaluation of their inhibition of Pf HGXPRT, Pv HGPRT 
and human HGPRT.  Phosphoramidate prodrugs of these compounds were then assessed for 
their antimalarial activity against Pf lines together with their toxicity in mammalian cells.  
2. Results and discussion 
2.1.  Chemistry 
The preparation of both series of ANbPs was divided into three consecutive stages. First, 
a hydroxy derivative of the designed symmetric acyclic moiety bearing two phosphonate 
functional groups was synthesized in several steps from basic starting materials. The second 
stage was a Mitsunobu reaction, which enabled the connection of the aliphatic moiety to the 
N-9 position of a purine base. The last stage was a sequence of reactions transforming the 
preformed derivative to the final inhibitor 
(Scheme 1 and 2).   
 
Figure 3. Docking of two new compounds into the crystal structure19 of human HGPRT in 
complex with inhibitor 1a (orange). A) alpha-branched ANbP, guanine derivative 18 (green), 
B) elongated ANbP, guanine derivative 39 (yellow) from the beta-branched series. 
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Scheme 1: Reaction sequence leading to the series of alpha-branched inhibitors. a) BnBr, 
NaH, DMF, -10 °C; b) DOWEX (50WX8 H+), 80% MeOH, 80 °C; c) Diethyl 
vinylphosphonate, Cs2CO3, t-BuOH, r.t.; d) H2(100 bar), Pd/C, MeOH, r.t. e) DIAD, PPh3, 6-
chloropurine, 2-amino-6-chloropurine or corresponding 7-deazapurines, THF, -30 °C; f) 
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CF3COOH, H2O, r.t.; g) K2CO3, DABCO, H2O, 120 °C; h) Br2, CCl4, DMF, r.t.; i) HCl(aq.), 
MW reactor 140 °C.; j) BrSi(CH3)3, CH3CN, r.t. 
In the alpha-branched series (Fig. 3A), the branching point of the acyclic moiety is at 
the alpha-position next to the heterocyclic base and terminal phosphonomethylether groups 
are extended to phosphonoethylether groups to maintain the original distance between the 
base and phosphonate groups as in the lead structure 1. The key intermediate 7, required for 
the alpha-branched series of inhibitors (Scheme 1) and their prodrugs, was prepared by a 5 
step reaction sequence. Commercially available 2-phenyl-1,3-dioxan-5-ol (compound 3, 
mixture of cis and trans) was protected by the reaction with benzyl bromide and sodium 
hydride in DMF at low temperature. Obtained crude benzyloxy derivative 4 was treated with 
DOWEX (50WX8 H+) in methanol to obtain dihydroxy derivative 5. In the next reaction step, 
intermediate 5 was reacted with diethyl vinylphosphonate under oxa-Michael addition 
conditions to obtain bisphosphonate intermediate 6, which was deprotected by hydrogenation 
to gain intended alcohol 7. 
In the beta-branched series (Fig. 3B), the basic scaffold of ANbP 1 is preserved, with 
only the tails in the acyclic moieties being elongated by one carbon to enable these 
compounds to reach further into the phosphonate binding sites. Preparation of the key 
intermediate 28 required for this beta-branched series (Scheme 2) started from commercially 
available 2-hydroxymethyl-1,3-propanediol, which was protected by the acid catalysed 
reaction with acetone. Obtained alcohol 24 was protected by the reaction with benzylbromide 
in DMF to form benzyloxy derivative 25, followed by acid catalysed hydrolysis of the 
isopropylidene protecting group to dihydroxy derivative 26. Diol 26 was treated with Diethyl 
vinylphosphonate under oxa-Michael addition conditions29 and afforded bisphosphonate 
intermediate 27. After subsequent hydrogenation alcohol 28 was obtained. 
Further reaction sequences leading to the alpha-branched and beta-branched inhibitors 
were based on parallel reaction procedures (Scheme 1 and Scheme 2). Hydroxy derivatives 7 
and 28 were processed under Mitsunobu reaction conditions to obtain 2-amino-6-
chloropurine, 6-chloropurine, 2-amino-6-chloro-7-deazapurine and 6-chloro-7-deazapurine 
derivatives 8, 9, 10, 11 and 29, 30, 31, 32. Intermediates 8, 9 and 29, 30 were hydrolysed by a 
mixture of trifluoroacetic acid and water to obtain 6-oxopurine derivatives 12, 13 and 33, 34. 
Acidic hydrolysis of 6-chloro-7-deazapurine derivatives under the same conditions was not 
successful. Thus, 7-deazapurine compounds 10, 11 and 31, 32 were hydrolysed by the 
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reaction with potassium carbonate and DABCO in water30,31 to form 6-oxo-7-deazapurine 
derivatives 16, 17 and 37, 38.  
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Scheme 2: Reaction sequence leading to the series of beta-branched inhibitors. a) dry acetone, 
pTsOH.H2O, molecular sieves, r.t.; b) BnBr, NaH, DMF, 0 °C; c) DOWEX (50WX8 H+), 
90% MeOH, 50 °C; d) Diethyl vinylphosphonate, Cs2CO3, t-BuOH, r.t.; e) H2(100 bar), Pd/C, 
MeOH, r.t.; f) DIAD, PPh3, 6-chloropurine, 2-amino-6-chloropurine or corresponding 7-
deazapurines, THF, -30 °C; g) CF3COOH, H2O, r.t.; h) K2CO3, DABCO, H2O, 120 °C; i) Br2, 
CCl4, DMF, r.t.; j) BrSi(CH3)3, CH3CN, r.t. 
8-bromopurine derivatives in the both series (Scheme 1 and 2) and the 8-
bromoderivative of compound 1a were synthesised to determine the effect of this base 
substitution (Scheme 3). Thus, compounds 12, 13 and 33, 34 were used for the preparation of 
bromo derivatives 14, 15 (Scheme 1) and 35, 36 (Scheme 2) by bromination with elementary 
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bromine in CCl4 and DMF. Synthesis of bromo derivative 46 started from previously prepared 
tetraester of bisphosphonate 1c19, which was transfromed to the corresponding 8-
bromoguanine derivative 45 by the same bromination procedure (Scheme 3).  
Scheme 3: Preparation of bromo derivative of leading structure 1. a) Br2, CCl4, DMF, r.t.; b) 
BrSi(CH3)3, CH3CN, r.t. 
Ester groups of bisphosphonates 12, 14, 15, 16, 17 (Scheme 1), 33, 34, 35, 36, 37, 38  
(Scheme 2) and 45 (Scheme 3) were cleaved with bromotrimethylsilane in acetonitrile, 
followed by hydrolysis and conversion to the corresponding sodium salts, to obtain target 
inhibitors 18, 20, 21, 22, 23 (Scheme 1), 39, 40, 41, 42, 43, 44 (Scheme 2) and 46 (Scheme 
3) for enzyme experiments. A classical synthetic method for simultaneous hydrolysis of 6-
chloro group and cleavage of ester groups by a microwave assisted reaction with hydrochloric 
acid32 was also tried. Thus, 6-chloropurine ester 9 was transformed directly to 6-oxopurine 
derivative containing free phosphonate functional groups, followed by conversion to the 
corresponding sodium salt of the final inhibitor 19 (Scheme 1).  
The highly polar bisphosphonates are unable to efficiently cross the cell membranes 
without masking the phosphonate functions and therefore the prodrug approach is generally 
used for the in vitro cell-based assays and in vivo testing.33,34,35 In our SAR-study, the ethyl 
ester of the natural amino acid, L-phenylalanine, was selected to mask both phosphonate 
groups of our inhibitors.36,37 This type of prodrug is more stable than ester prodrugs. In 
solution no hydrolysis was observed at pH 7. In plasma/cells the four prodrug-moieties are 
gradually cleaved, after several hours part of the intact prodrug can be still observed. 
Preparation of these phosphoramidates prodrugs for both series of ANbP inhibitors for cell-
based assays started from the corresponding alkyl diesters (Scheme 4). Intermediates 12, 13, 
16, 17 and 33, 34, 37, 38 were transformed to corresponding phosphoramidate prodrugs 47, 
48, 49, 50, 51, 52, 53 and 54 by treatment with bromotrimethylsilane in acetonitrile, followed 
by reaction with L-phenylalanine ethyl ester and 2,2′-dipyridyl disulfide and 
triphenylphosphine in dry pyridine.38 
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Direct preparation of phosphoramidate prodrugs of 8-bromo ANbPs from the 
corresponding diesters was not possible. Under standard reaction conditions a mixture of three 
UV absorbing products was formed (one of these was desired prodrug), with almost the same 
retention factors in various chromatography systems. Therefore a different procedure was 
developed for direct bromination of the final prodrugs. After preliminary unsuccessful 
experiments with various bromination conditions (elementary bromine, NBS, various 
concentration and temperature), relatively universal reaction conditions (microwave reactor, 
2.5 eq. of NBS, 1,4-dioxane, 100 °C and short reaction time 15-20 minutes) were found. 
Using this method, prodrugs 47, 48, 51, 52 and previously published19 59 were transformed to 
the corresponding 8-bromopurine prodrugs 55, 56, 57, 58 and 60 (Scheme 4). 
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Scheme 4: Preparation of phosphoramidate prodrugs of prepared/discussed inhibitors. a) 1. 
BrSi(CH3)3, CH3CN, r.t, 2. PPh3, Aldrithiol, (L)-NH2CH(Bn)COOEt.HCl, Et3N, pyridine, 70 
°C; b) NBS, 1,4-dioxane, MW, 100 °C. 
 
 
2.2.  Inhibition of human HGPRT, Pf HGXPRT and Pv HGPRT by the ANbPs  
The ANbPs synthesised in Series 3 (Scheme 2, Table 1) are based on {[(2-[(guanin-9H-
yl)methyl]-propane-1,3-diyl)bis(oxy)]bis(methylene)}diphosphonic acid (1a, Fig. 2) which 
has Ki values for the human, Pf and Pv enzymes of 30, 70 and 600 nM, respectively (Table 1, 
Series 1).19 A crystal structure of 1a in complex with human HGPRT shows that one of the 
phosphonate groups reaches into the 5′-phosphate binding pocket (Fig. 3) but the second 
phosphonate group projects out of the active site rather than occupying the PPi binding site 
which is filled by a sulfate ion.  
In Series 3 (Table 1), symmetry was maintained, as was the position of the oxygen atoms 
in the linker (cf Series 1), but an extra carbon was inserted between the oxygen and the 
phosphonate group in both branches (39 - 44; Scheme 2).  The aim of this addition was to 
attempt to place the second phosphonate group in the same position as the sulfate group which 
occupies the PPi binding site (Fig. 3B).  However, for symmetry purposes, this also meant 
that there is an extra carbon atom in the linker attaching the base to the phosphonate group 
designed to be located in the 5′-phosphate binding pocket. 
  Another bisphosphonate, (9-[1,3-bis(phosphonomethoxy)propan-2-yl]guanine 
(compound 2, Fig. 2) was also previously investigated.19 In this compound, the branching 
point of the acyclic moiety was moved to the alpha-position next to the heterocyclic base.  
This compound is a weak inhibitor of all three enzymes with Ki values of 37, 2 and 18 µM, 
respectively.  However, there are only 4 atoms in the linker connecting the N9 atom to the 
phosphorous atom in comparison to 1a where there are 5. Therefore, it was postulated that the 
low Ki values may be due to the fact that the distance between the N9 atom of the base and the 
phosphonate groups is too short to allow the phosphonyl oxygens to form strong interactions 
with active site amino acid residues. An alternative explanation is that this structure does not 
allow either of the two phosphonate groups to be orientated into areas in the active site that 
bind phosphate groups i.e. the 5′-phosphate or PPi.  There is no available crystal structure of 
this compound in complex with any of the 6-oxopurine PRTases. Thus, to try to distinguish 
between the two possibilities above and to try in improve the inhibition of the enzymes, a new 
series of ANbPs was designed whereby there was only one difference with (9-[1,3-
bis(phosphonomethoxy)propan-2-yl]guanine (2). This difference is that the linker was 
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lengthened by one carbon atom between the oxygen atom and the phosphorous atom in both 
branches of acyclic moiety (18 - 23; Scheme 1) giving it a better chance of reaching the 
predicted sites.   
In both of the two new series of compounds, six different purine bases were attached to 
the acyclic moieties. Guanine or hypoxanthine because these are the naturally-occurring 
purine bases; 8-bromoguanine as it has been shown39 that substitution of this base for guanine 
in 9-[(N-phosphonoethyl-N-phosphonoethoxyethyl)-2-aminoethyl]-guanine results in a 3-4 
fold decrease in the Ki value for the two parasite enzymes; and the unnatural 7-deaza 
nucleobases to study the role of the interaction of N7 in natural nucleobases. The Ki values of 
the ANbPs for human HGPRT, Pf HGXPRT and Pv HGPRT are shown in Table 1. 
Compound Ki (µM) 
No. Base Acyclic moiety human HGPRT Pf HGXPRT Pv HGPRT 
1a G Series 1 (beta, 6/6) 
 
 
0.03±0.002g 0.07±0.01g 0.6±0.07g 
1b Hx 1±0.1g 5±1g 2±0.3g 
46 8-Br-G 4±1 1±0.3 89±15 
18 G Series 2 (alfa, 6/6) 
 
B
O
O
P(O)(OH)2
P(O)(OH)2  
0.3±0.1 0.2±0.06 21±7 
19 Hx 3±1 0.7±0.2 21±6 
20 8-Br-G 19±4 4±1 153±20 
21 8-Br-Hx NIa NIa NIa 
22 7-deaza-G 5±1 6±2 49±10 
23 7-deaza-Hx NIb NIb NIb 
39 G Series 3 (beta, 7/7) 
 
 
0.1±0.03 0.1±0.02 0.16±0.02 
40 Hx 1.5±0.5 NIc 6±1 
41 8-Br-G 0.25±0.07 NId 1.6±0.08 
42 8-Br-Hx 9.7±1.0 NIe NIe 
43 7-deaza-G 1±0.3 1±0.4 1.5±0.6 
44 7-deaza-Hx 17±4 NIf NIf 
a
no inhibition at [I] = 35 µM; bno inhibition at [I] = 42 µM; cno inhibition at [I] = 46 µM; dno 
inhibition at [I] = 32 µM; eno inhibition at [I] = 29 µM; fno inhibition at [I] = 31 µM; gData 
from 19     
Table 1: Summary of Ki values for ANbPs inhibitors of human, Pf HGXPRT and Pv HGPRT.  
 
 
Comparing beta-branched compounds 1a and 1b with 39 and 40, the addition of the 
extra carbon atom in the linker led to a small increase in the Ki values for human and Pf with 
guanine as the base though, for Pv, there is a small decrease (cf Series 1 and 3, Table 1). 
When guanine is replaced by hypoxanthine, the Ki value increases for all enzymes but this is 
more pronounced for Pf HGXPRT as no inhibition was observed at relatively high 
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concentrations of the ANbP (46 µM). Thus, only 39 in Series 3 is an efficient inhibitor of Pf 
HGXPRT though the compounds are reasonable inhibitors of the other two enzymes (0.1-17 
µM; Table 1). One factor that contributes to this increase for Pf HGXPRT could be the 
increased length of the linker connecting the phosphonate group that reaches into the 5′-
phosphate binding pocket to the purine base. Previous studies have shown that Pf HGXPRT 
prefers only five atoms between the N9 of the purine base and this phosphorous atom.31 In 
comparison, the human enzyme can adapt more easily to this change in length.31 
 For Series 1, 2 and 3 the addition of a bromine atom at position 8 in the purine ring 
led to an increase in Ki values (Table 1, cf compound 46 with 1a, 20 and 21 with 18 and 19 
and 43 with 39 and 40). However, for the aza-ANP 9-[(N-phosphonoethyl-N-
phosphonoethoxyethyl)-2-aminoeth-yl]-8-bromoguanine, the Ki values for the two parasite 
enzymes are 2-3-fold lower compared with 9-[(N-phosphonoethyl-N-phosphonoethoxyethyl)-
2-aminoethyl]-guanine. The crystal structures showed that this decrease in the Ki for 8-bromo 
derivative was due to a rotation of the purine ring which resulted in increased interactions 
between the phosphonyl oxygens and active site residues (PDB codes: 4RAB and 4RAD).39 
Clearly, this has not occurred with the ANbPs and it is concluded that the decrease in 
inhibition constant is due to the fact that the orientation of the base with a bromine attached at 
position 8 resulted in a decrease in such interactions.  
 The replacement of N7 in the purine base with a carbon, as in the 7-deaza ANbPs 43 
and 44 (Series 3) and 22 and 23 (Series 2) increased the Ki values for all three enzymes. 
7-Deazaguanine is not a substrate for either the human or Pf enzymes nor is it a competitive 
inhibitor.7 Thus, it is likely that ANbPs with this base attached may not be as good as when 
the base is either guanine or hypoxathine. These four ANbPs (22, 23, 43 and 44; Table 1) are 
very weak inhibitors for all three enzymes suggesting that all three attachments have to be 
located in their optimal position for tight binding to occur. However, the interactions between 
the phosphonyl oxygens and active site residues are strong enough to allow the very weak 
binding 7-deaza bases to be located in the active site. Where they are positioned relative to 
guanine or hypoxanthine is not known. 
In the alpha-branched series of ANbPs (Scheme 1; Series 2, Table 1), the addition of 
the extra carbon between the oxygen atoms in the linker and the phosphonate groups had a 
positive effect on the Ki for the human enzyme compared with 2 (Fig. 2).  This elongation of 
both branches resulted in a 123 fold decrease in the Ki (0.3 µM for 18 and 37 µM for 9-[1,3-
bis(phosphonomethoxy)propan-2-yl]guanine (2).19 For Pf HGXPRT, this extra carbon atom 
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decreased the Ki by10-fold (0.2 from 2 µM). However, it has no effect on the Ki for Pv 
HGPRT (cf 21 with 18 µM). This is again consistent with the fact that Pf HGXPRT is 
intolerant of compounds which contain more than five atoms in the linker between the base 
and the phosphonate group though the human and Pv enzymes are more forgiving and can 
adapt their structures to accommodate the extra atom. Compared with the leading structure 1a, 
the corresponding guanine derivative 18 is a less potent inhibitor for all three enzymes.  
 
2.3. In vitro antimalarial study in erythrocyte cell cultures infected by Plasmodium 
falciparum and cytotoxicity study in A549 lung carcinoma cells 
 
These ANbP-based inhibitors contain two strongly polar and charged phosphonate groups. 
Previous studies have shown that such compounds are not effectively transported into 
erythrocytes and therefore cannot reach the Pf parasites in the cell-culture assays.19 However, 
phosphoramidate prodrugs (Scheme 4) of aza-ANPs have been shown to possess antimalarial 
activity39,40 so prodrugs of these new compounds were synthesised (Scheme 4) to evaluate 
their effectiveness in vitro. The results of these in vitro tests are summarized in Table 2. 
Compared to the leading compounds 59 and 61,19 three of the new prodrugs (48, 49 and 53) 
exhibited improved antimalarial activity against two Pf lines (D6 and W2) with IC50 values 
ranging between 0.8-2.1 µM. However, the percentage of the prodrug that actually enters the 
parasite cell and what percentage is then hydyrolysed to the active component is unknown. 
Based on previous experience with the successful antiviral prodrugs, the L-phenylalanine 
containing phosphoramidates were selected as model prodrugs with reasonable stability and 
penetration properties. However, for future development of these compounds as antimalarials, 
the nature of the prodrug needs to be improved and specifically designed for uptake into 
Plasmodium cells. The cytotoxicity of the target prodrugs was measured in human A549 lung 
carcinoma cells and the results are summarized in Table 2. These compounds have low 
cytotoxicity (CC50) values between 23 to >300 µM. Thus, the prodrugs in Series 1 and 2 
exhibited low or minimal cytotoxicity (>100 µM) and it is only for the last five compounds in 
Series 3 that any levels of cytotoxicitiy were recorded. There is, to date, no rational 
explanation for this observation. The most active derivatives 48, 49 and 53 have CC50 values 
>300, >300 and 95 µM, respectively, and thus exhibit a favourable selectivity index. The data 
indicate that even the prodrugs of potent inhibitors of human HGPRT (guanine derivatives 59, 
47 and 51) have little if any cytostatic effect, since purine salvage pathway is dispensable in 
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human cells. Also, the lack of cytostatic activity (CC50 > 300 µM) indicates that the 
compounds have no inhibitory effect on other human enzymes with a crucial role in cell 
proliferation. The finding fully agrees with the proposed mode of action via the inhibition of 
Pf HGXPRT. 
 
B = purine base; aPf strain sensitive to most drugs; bChloroquine- and pyrimethamine-resistant 
Pf strain; cHuman lung carcinoma cells; dData from 19; ND = not done. 
Table 2: Antimalarial activity and cytotoxicity of ANbP prodrugs in cell culture assays. 
 
3. Conclusions  
Based on our initial discovery19 that [(2-[(guanin-9H-yl)methyl]-propane-1,3-
diyl)bis(oxy)]bis(methylene)diphosphonic acid  (1a) is a nanomolar inhibitor of Pf HGXPRT 
(70 nM) while (9-[1,3-bis(phosphonomethoxy)propan-2-yl]guanine (2, Fig. 2) is a very weak 
inhibitor (2 µM), two new series of symmetrical ANbPs were synthesised.  For the 
compounds which are branched at the alpha-position adjacent to the N9 of the purine base 
(Series 2, Table 1), the insertion of an extra carbon atom in both linkers decreased the Ki 
values for the human and Pf enzymes (123 and 10-fold compared to 2, Fig. 2) when guanine 
is the base, but was ineffective against the Pv enzyme. For beta-branched Series 3, 
Compound               Y = CH(CH2Ph)COOEt IC50 (µM) CC50 (µM) 
No. Base Acyclic moiety D6a W2b A549c 
59 G 
B O
O
P(O)(NHY)2
P(O)(NHY)2
 
9.7 ± 1.6d 7.1 ± 2.1d >300d 
61 Hx 3.8 ± 0.5d 4.0 ± 0.9d 101 ± 17d 
60 8-Br-G ND ND ND 
47 G 
 
10.0 ± 0.9 9.4 ± 0.9 >300 
48 Hx 1.5 ± 0.4 1.7 ± 0.6 >300 
55 8-Br-G 4.4 ± 1.0 7.0 ± 0.5 ND 
56 8-Br-Hx ND ND 278 ± 4 
49 7-deaza-G 0.8 ± 0.1 1.1 ± 0.3 >300 
50 7-deaza-Hx ND ND 130 ± 41 
51 G 
 
5.1 ± 0.8 6.9 ± 1.7 >300 
52 Hx 1.7 ± 0.4 4.6 ± 0.1 66 ± 27 
57 8-Br-G 22.1 ± 2.7 21.3 ± 5.0 94 ± 18 
58 8-Br-Hx ND ND 43 ± 1 
53 7-deaza-G 0.8 ± 0.1 2.1 ± 0.2 95 ± 27 
54 7-deaza-Hx ND ND 23 ± 6 
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lengthening the linkers by one carbon resulted in an increase in the Ki for Pf HGXPRT except 
when the base was guanine.  Thus, small chemical modifications to the symmetric acyclic 
chain has a significant effect on the potency and selectivity of binding of the ANbPs to all 
three enzymes. New types of purine bases were also introduced to obtain more complex set of 
data for ongoing SAR-study.  
Three of the prodrugs (48, 49, 53; Table 2) for the new inhibitors exhibited improved in vitro 
antimalarial activity against two Pf lines (D6 and W2) with IC50 values ranging between 0.8-
2.1 µM.  Two of these compounds have no observable cytotoxicity in human cell line (>300 
µM) and thus have a good selectivity index. The major problem that needs to be overcome is 
uptake by the parasite.  We have made a start by the introduction of model phosphoramidate 
prodrugs that are active in cell assays, but there is no clear correlation between activities of 
inhibitors and antimalarial activity of their prodrugs. There are several factors that could 
contribute to variable uptake, these include: (i) entry into the red blood cell (ii) hydrolysis of 
the prodrug attachments within the red blood cell and (iii) entry into the parasite.   In our 
view, these factors appear to make a major contribution to determining the final IC50 values 
obtained in cell based assays. 
 
4. Experimental 
Synthesis and Analytical Chemistry 
Unless stated otherwise, solvents were evaporated at 40 °C/2 kPa, and compounds were dried 
in vacuum oven at 2 kPa. Tetrahydrofuran (THF) was distilled with lithium aluminum hydride 
pellets under argon. Tert-Butanol was stored over annealed molecular sieves (4 Å). 
1H and 13C NMR spectra were measured on a Avance 500 spectrometer (500 MHz and 126 
MHz) in DMSO-d6, D2O or D2O-(NaOD additive) and referred to TMS, residual solvent 
signal or added solvent (tBuOH or 1,4-dioxan). Complete assignment is based on 
heteronuclear correlation experiments HSQC and H, C-HMBC. Chemical shifts (δ) are in 
ppm and coupling constants (J) in Hz. The numbering system for the assignment of NMR 
signals is given for the majority of the compounds individually. GC/MS spectra were 
measured on Agilent 5975B MSD spectrometer coupled to 6890N gas chromatograph. 
Determination of low-resolution mass spectra is described below (procedure 1 a procedure 2). 
High resulution mass spectra were measured: on Q-Tof micro (Waters) using ESI technique 
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for low-resolution mass spectra, followed by LTQ Orbitrap XL (Thermo Fisher Scientific) 
spectrometer using ESI technique for high-resolution mass spectra. 
For flash chromatography, Teledyne ISCO CombiFlash Rf200 with dual λ absorbance 
detector and various types of columns were used: a) original Teledyne ISCO columns 
RediSepRf® variation HP Silica GOLD in sizes 12 g, 40 g, 80 g and 120 g; b) original 
Teledyne ISCO columns RediSepRf® variation HP C18 Aq GOLD in sizes 50 g and 100 g; c) 
column CHROMABOND Flash DL 40, DL 80, DL 120 and DL 200, filled by FLUKA silica 
gel 60. Separation of UV non-absorbing substances were made: a) with internal UV 
absorption standard (like caffeine) with similar Rf as required substance; b) by capturing all 
fractions followed by analysis. 
UPLC-MS: 
Procedure 1: Analytical sample was prepared so that 50 µl reaction mixture or 
chromatographic fraction was diluted in suitable solvent (MeOH or acetonitrile) to a 
concentration about 1 mg of sample in 1 ml of solution. The mixture was then diluted to a 1-2 
ml volume and filtered over syringe filter (0.22 µM, membrane material = PVDF). 
Samples were tested by the universal LC method (eluent H2O/CH3CN, gradient 0-100 %, run 
length 7 minutes) and time-tested MS method (ESI+, cone voltage = 30V, mass detector range 
~ 100-1000 Da in standard case; 500-1600 Da for measurement of prodrugs). 
Analytical arrangement contains: Waters UPLC H-Class Core System, (column Waters 
Acquity UPLC BEH C18 1.7 µm, 2.1x100 mm), Waters Acquity UPLC PDA detector, Mass 
spectrometer Waters SQD2. 
Procedure 2: This procedure is suitable for measurement of free phosphonic acids or their 
sodium salts. The procedure is almost identical as described above in Procedure 1, but the 
samples are diluted in water and different MS method (ESI-, detector range ~ 100-1000 Da) is 
used.  
Synthetic procedures 
General procedure for Mitsunobu reaction (Method A): 
To a solution of triphenylphosphine (3.5 g, 13.4 mmol) in dry THF (50 ml) cooled to –30 °C 
under argon atmosphere diisopropyl azadicarboxylate (DIAD, 2.4 ml, 12.2 mmol) was added. 
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The mixture was stirred for 30 min to preform a complex. The solution of the corresponding 
alcohol (4 mmol) in dry THF (30 ml) and 6-chloropurine (1 g, 6.4 mmol = 1.6 eq.) or 6-
chloro-7-deazapurine (1 g, 6.4 mmol = 1.6 eq.) was added to the preformed complex and the 
reaction flask was again filled with argon. The resulting mixture was slowly warmed up to 
room temperature and stirred for two days. MeOH (30 ml) was added to dissolve all possible 
heterogeneous particles. Solvent was evaporated, and the crude mixture was purified by flash 
chromatography (silica gel; eluent CHCl3/MeOH, gradient 1-10%). The pure product was 
obtained as a yellowish solid or a foam. 
 
General procedure for the Mitsunobu reaction (Method B): 
Starting from 2-amino-6-chloropurine or 2-amino-6-chloro-7-deazapurine and the 
corresponding alcohol procedure was identical as described above – Method A. Then after the 
stirring of the reaction mixture for two days, water (30 mL) and MeOH (30 mL) were added 
and the mixture was heated at 80 °C for 30 hours. Solvent was evaporated, the residue was 
codistilled with toluene, and the crude mixture purified by flash chromatography (silica gel; 
eluent CHCl3/MeOH, gradient 2-15%).  
 
General procedure for hydrolysis of 6-chloropurine and 2-amino-6-chloropurine 
derivatives to corresponding 6-oxopurine and 2-amino-6-oxopurine derivatives (Method C): 
The 6-chloropurine or 2-amino-6-chloropurine derivative (4.13 mmol) was dissolved in 
aqueous trifluoroacetic acid (75%, 60 mL) and stirred overnight at room temperature. The 
solvent was evaporated and the residue was codistilled with water (3×) and toluene (2×). The 
crude product was purified by flash chromatography (silica gel; eluent CHCl3/MeOH, 
gradient 2-15%). Pure product was obtained as a solidified oil. 
 
General procedure for hydrolysis of 6-chloro-7-deazapurine and 2-amino-6-chloro-7-
deazapurine derivatives to corresponding 6-oxo-7-deazapurine and 2-amino-6-oxo-7-
deazapurine derivatives (Method D): 
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The appropriate 6-chloropurine derivative (3 mmol) was dissolved or suspended in water (40 
mL) containing K2CO3 (1.69 g, 12.2 mmol) and DABCO (0.69 g, 6.2 mmol). The reaction 
mixture was stirred and heated to 120 °C for 1-4 hours. The resultant solution was cooled 
down, neutralized by 1 M HCl and a product extracted to CHCl3 (3x 50 ml). Organic phase 
was washed with water (2x 100 ml), followed by brine (1x 100 ml) and dried over MgSO4. 
Compounds were purified by flash chromatography (silica gel; CHCl3/MeOH, gradient 2-10 
%). Reaction was monitored by LC-MS (Procedure 1). 
 
General procedure for synthesis of sodium salts of free bisphosphonates (Method E): 
A mixture of bisphosphonic acid diester (diisopropyl or diethyl ester) (1 mmol), acetonitrile 
(20 ml) and BrSiMe3 (2 ml) was stirred overnight at room temperature. After evaporation, the 
residue was stirred with MeOH:water (1:1, 100 ml) for 2 hours at room temperature. The 
solvent was evaporated in vacuo. The residue was dissolved in solution of TEAB (5 ml 2M 
aqueous TEAB), evaporated in vacuo and codistilled with water (3x). That TEAB-salt was 
purified by flash chromatography (C18 silica gel, 0.125 M aqueous TEAB/MeOH, gradient 0-
40%) and evaporated in vacuo and codistilled with water (3x). The residue was dissolved in 
small volume of water (5 ml) and percolated through DOWEX (50WX8 Na+, 5 g) to obtain 
sodium salt of the bisphosphonic acid. Filtrate was partially evaporated and prepared for 
following manipulation by lyophilisation from water. 
 
General procedure for bromination of 6-oxopurine derivatives (Method F): 
To a solution of corresponding 6-oxopurine derivative (2 mmol) in DMF (10 ml), 0.3 M 
solution of bromine in CCl4 (13 ml, 4 mmol of Br2, 2 eq.) was added. Reaction mixture was 
stirred for 2-12 hours at room temperature. The mixture was evaporated in vacuo, codistilled 
with toluene (3x) and purified by flash chromatography (silica gel; CHCl3/MeOH, gradient 1-
10%). Reaction was monitored by LC-MS (Procedure 1). The product was obtained as 
colourless/yellowish solidified oil. 
 
General procedure for synthesis of tetra-(ʟ-phenylalanine ethylester) prodrugs of 
bisphosphonates (Method G): 
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Bisphosphonic acid diester (diisopropyl or diethyl ester) (1 mmol) was codistilled with dry 
acetonitrile (2x). Dry acetonitrile (20 ml) and bromotrimethylsilane (2 ml) were mixed with 
bisphosphonic acid diester and stirred overnight at room temperature under argon. After 
evaporation in vacuo and codistillation with dry acetonitrile (3x) (without any contact with 
air), the flask was purged with argon and amino acid ester hydrochloride (2.5 g, 10.88 mmol, 
dried in vacuo at 30 °C and 0.1 mbar for 1 day), dry triethylamine (5 mL), and dry pyridine 
(15 mL) were added and this mixture was stirred and heated to 70 °C. Solution of 2,2’-
dipyridyldisulfide (3.4 g, 15.4 mmol) and triphenylphosphine (4 g, 15.4 mmol) in 15 mL of 
dry pyridine under argon was added immediately. The resulting mixture was heated at 70 °C 
for 3 days to reach the full conversion. After cooling to room temperature, the richly yellow 
solution was evaporated in vacuo and the residue was purified first by flash chromatography 
(silica gel; CHCl3/MeOH, gradient 2-15%), followed by flash chromatography again (C18 
silica gel, eluent H2O/MeOH, gradient 70-100%). The product was obtained as 
colourless/yellowish foam and prepared for following manipulation by lyophilisation from 
dioxan. 
 
General procedure for bromination of tetra-(ʟ-phenylalanine ethylester) prodrug of 
bisphosphonates (Method H): 
The corresponding parent prodrug (0.15 mmol) and NBS (67 mg, 0.38 mmol, 2.5 eq.) were 
placed into 10 ml MW reactor cuvette and dioxan (6 ml) was added. Cuvette was filled with 
argon and sealed with a septum. Reaction mixture was stirred in MW reactor at 100 °C for 20 
min. The mixture was evaporated and purified first by flash chromatography (silica gel; eluent 
CHCl3/MeOH, gradient 2-15%), followed by flash chromatography again (C18 silica gel, 
eluent H2O/MeOH, gradient 70-100%). Compounds were prepared for following 
manipulation by lyophilisation from dioxan. 
 
2-(Benzyloxy)propane-1,3-diol (5) 
To a solution of 2-phenyl-1,3-dioxan-5-ol (3) (18 g, 100 mmol) in dry DMF (500 ml) cooled 
to -10 °C under argon atmosphere, NaH (60% suspension in mineral oil; 6 g, 150 mmol, 1.5 
eq.) was added. Reaction flask was filled with argon again and the mixture was stirred for 30 
min. to preform sodium salt of alcohol. Benzyl bromide (14.6 ml, 125 mmol, 1.25 eq.) was 
  
 20 
added and reaction flask was filled with argon again. The resulting mixture was warmed up to 
room temperature and stirred overnight. Water (75 ml) was added and mixture was stirred for 
30 min. Solvents were evaporated in vacuo and the residue was codistilled with toluene (3x). 
Crude material was suspended in EtOAc (250 ml) and mixture of saturated solution of NH4Cl 
(40 ml) and water (160 ml). Water phase was separated and extracted with EtOAc (2x 150 
ml). The organic phase was collected (250+150+150 ml) and washed by water (2x 200 ml), 
followed by brine (1x 200ml) and dried over MgSO4. The solution was filtered and 
evaporated in vacuo. The residue (crude substance 4, brown oil) was diluted in MeOH (320 
ml) and water (80 ml). DOWEX (50WX8 H+, 10 g) was added and mixture was heated at 80 
°C and stirred for 5 hours. Reaction mixture was cooled down to room temperature and 
filtered through the frit (S3), evaporated in vacuo and codistilled with toluene (3x). Crude 
product was purified by flash chromatography (silica gel; eluent CHCl3/MeOH, gradient 2-
5%) to obtained 12.1 g (66%) of 5 as colourless oil. Reaction was monitored by TLC 
(Procedure 5) and presence of product was confirmed by GC-MS. Pure product was used in 
the next reaction step without additional characterisation. 
 
Tetraethyl {[(2-benzyloxypropane-1,3-diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (6) 
Diol 5 (12.1 g, 66 mmol) and cesium carbonate (21.5 g, 66 mmol) were placed into 250 ml 
reaction flask.  Dry tert-Butyl alcohol (70 ml) was added, the flask was sealed with a septum 
and filled with argon. Diethyl vinylphosphonate (28 ml, 185 mmol, 2.8 eq.) was added into 
the flask and the mixture was vigorously stirred for two days. The reaction mixture was 
diluted with water and extracted with EtOAc (3x 200 mL). The organic phase was collected, 
washed with water (2x 200 ml), followed by brine (1x 200ml) and dried over MgSO4. The 
solution was filtered and evaporated in vacuo. Crude product was purified by flash 
chromatography (silica gel; eluent hexan:EtOAc [6:4]/MeOH gradient 0-10%) to obtained 
26.2 g (78%) of 6 as colourless oil. Pure product was used in the next reaction step without 
additional characterisation. MS (ESI+) m/z = 511.3 [M + H]+ 
 
Tetraethyl {[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (7) 
Benzyloxy derivative 6 (25.8 g, 50.5 mmol) was diluted in MeOH (350 ml) and transferred to 
autoclave. Pd paste (7g Pd/C 10% and 15 ml water) was added. Autoclave was sealed up and 
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filled with argon followed by H2. Reaction mixture was stirred under H2 (100 bar) for two 
days at room temperature, H2 was refiled to a pressure of 100 bar four times. Autoclave was 
filled with argon and reaction mixture was filtered through a kieselguhr  pad. The filtrate was 
evaporated in vacuo and purified by flash chromatography (silica gel; eluent hexan:EtOAc 
[6:4]/MeOH gradient 0-10%). Afforded 20.9 g (99%) of 7 as colourless oil. 
1H NMR (DMSO-d6): 4.83 [d, J(OH,1) = 4.9 Hz, OH]; 
3.93-4.03 [m, 8H, CH2CH3]; 3.68 [m, H-1]; 3.57 [dt, 4H, 
J(H,C,C,P) = 13.0 Hz, J(CH2,CH2) = 7.3 Hz, CH2CH2-P]; 
3.37 [dd, 2H, J(gem) = 10.0 Hz, J(2a,1) = 4.9 Hz, H-2a]; 
3.30 [dd, 2H, J(gem) = 10.0 Hz, J(2b,1) = 6.0 Hz, H-2b]; 2.04 [dt, 4H, J(H,C,P) = 18.2 Hz, 
J(CH2,CH2) = 7.3 Hz, CH2-P]; 1.24 [t, 12H, J(CH3,CH2) = 7.1 Hz, CH3]. 13C NMR (DMSO-
d6): 72.27 [C-2]; 68.59 [C-1]; 64.84 [d, J(C,C,P) = 1.4 Hz, CH2CH2-P]; 61.15 [d, J(C,O,P) = 
6.2 Hz, CH2CH3]; 26.15 [d, J(C,P) = 136.9 Hz, CH2-P]; 16.44 [d, J(C,C,O,P) = 5.9 Hz, CH3]. 
MS (ESI+) m/z = 421.0 [M + H]+. 
 
Tetraethyl {[(2-(2-amino-6-chloropurin-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (8) 
From compound 7 (4.43 g, 10.5 mmol) according to Method B, afforded 2.63 g (44%) of 8 as 
yellowish foam. 
1H NMR (DMSO-d6): 8.23 [s, 1H, H-8]; 6.90 [bs, 2H, 
NH2]; 4.72 [m, 1H, H-1’]; 3.87-3.94 [m, 10H, H-2’a, 
CH2CH3]; 3.77 [dd, 2H, J(gem) = 10.5 Hz, J(2’b,1’) = 4.9 
Hz, H-2’b]; 3.51-3.63 [m, 4H, CH2CH2-P]; 1.93-2.06 [m, 
4H, CH2-P]; 1.18 and 1.16 [t, 12H, J(CH3,CH2) = 7.1 Hz, 
CH3]. 13C NMR (DMSO-d6): 159.85 [C-2]; 154.45 [C-4]; 
149.48 [C-6]; 142.39 [C-8]; 123.33 [C-5]; 68.52 [C-2’]; 64.90 [d, J(C,C,P) = 1.8 Hz, 
CH2CH2-P]; 61.09-61.17 [m, CH2CH3]; 53.83 [C-1’]; 25.92 [d, J(C,P) = 137.1 Hz, CH2-P]; 
16.39 and 16.38 [d, J(C,C,O,P) = 5.8 Hz, CH3]. MS (ESI+) m/z = 572.1 [M + H]+. 
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Tetraethyl {[(2-(6-chloropurin-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (9) 
From compound 7 (3.36 g, 8 mmol) according to Method A, afforded 3.6 g (80%) of 9 as 
yellowish foam. 
1H NMR (DMSO-d6): 8.82 [s, 1H, H-8]; 8.78 [s, 1H, H-
2]; 5.04 [m, 1H, H-1’]; 3.99 [dd, 2H, J(gem) = 10.6 Hz, 
J(2’a,1’) = 7.5 Hz, H-2’a]; 3.84-3.92 [m, 10H, H-2’b, 
CH2CH3]; 3.51-3.64 [m, 4H, CH2CH2-P]; 1.90-2.03 [m, 
2H, CH2-P]; 1.16 and 1.15 [t, 12H, J(CH3,CH2) = 7.0 Hz, 
CH3]. 13C NMR (DMSO-d6): 152.33 [C-4]; 151.60 [C-2]; 
149.19 [C-6]; 146.87 [C-8]; 130.87 [C-5]; 68.44 [C-2’]; 64.87 [d, J(C,C,P) = 2.0 Hz, 
CH2CH2-P]; 61.03-61.11 [m, CH2CH3]; 25.88 [d, J(C,P) = 137.4 Hz, CH2-P]; 16.35 and 16.33 
[d, J(C,C,O,P) = 5.8 Hz, CH3]. MS (ESI+) m/z = 557.2 [M + H]+. 
 
Tetraethyl {[(2-(2-amino-6-chloro-7-deazapurin-9-yl)propane-1,3-
diyl)bis(oxy)]bis(ethane-2,1-diyl)}bis(phosphonate) (10) 
From compound 7 (4.1 g, 9.75 mmol) according to Method B, afforded 2.61 g (47%) of 10 as 
yellowish solid. 
1H NMR (DMSO-d6): 7.31 [d, 1H, J(8,7) = 3.8 Hz, H-8]; 
6.61 [bs, 2H, NH2]; 6.30 [d, 1H, J(7,8) = 3.8 Hz, H-7]; 
4.86 [m, 1H, H-1’]; 3.86-3.95 [m, 8H, CH2CH3]; 3.79 [dd, 
1H, J(gem) = 10.4 Hz, J(2’a,1’) = 7.2 Hz, H-2’a]; 3.72 
[dd, 1H, J(gem) = 10.4 Hz, J(2’b,1’) = 5.0 Hz, H-2’b]; 
3.50-3.60 [m, 4H, CH2CH2-P]; 1.94-2.01 [m, 4H, CH2-P]; 
1.15-1.19 [m, 12H, CH3]. 13C NMR (DMSO-d6): 159.55 [C-2]; 154.07 [C-4]; 151.11 [C-6]; 
124.73 [C-8]; 108.79 [C-5]; 98.89 [C-7]; 69.23 [C-2’]; 64.86 [CH2CH2-P]; 61.10-61.17 [m, 
CH2CH3]; 53.15 [C-1’]; 25.99 [d, J(C,P) = 137.0 Hz, CH2-P]; 16.37-16.43 [m, CH3]. MS 
(ESI+) m/z = 571.2 [M + H]+. 
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Tetraethyl {[(2-(6-chloro-7-deazapurin-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (11) 
From compound 7 (3.43 g, 8.17 mmol) according to Method A, afforded 3.61 g (62%) of 11 
as yellowish foam. 
1H NMR (DMSO-d6): 8.61 [s, 1H, H-2]; 7.94 [d, 1H, 
J(8,7) = 3.7 Hz, H-8]; 6.66 [d, 1H, J(7,8) = 3.7 Hz, H-7]; 
5.17 [m, 1H, H-1’]; 3.79-3.92 [m, 12H, H-2’, CH2CH3]; 
3.48-3.62 [m, 4H, CH2CH2-P]; 1.91-1.98 [m, 4H, CH2-P]; 
1.15 and 1.13 [t, 12H, J(CH3,CH2) = 7.0 Hz, CH3]. 13C 
NMR (DMSO-d6): 151.35 [C-4]; 150.76 [C-6]; 150.35 
[C-2]; 130.01 [C-8]; 116.97 [C-5]; 98.94 [C-7]; 69.21 [C-2’]; 64.88 [d, J(C,C,P) = 1.6 Hz, 
CH2CH2-P]; 61.12-61.19 [m, CH2CH3]; 54.13 [C-1’]; 25.98 [d, J(C,P) = 137.1 Hz, CH2-P]; 
16.42 and 16.40 [d, J(C,C,O,P) = 5.9 Hz, CH3]. MS (ESI+) m/z = 556.2 [M + H]+. 
 
Tetraethyl {[(2-(guanine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (12) 
From compound 8 (562 mg, 0.98 mmol) according to Method C, afforded 404 mg (74%) of 
12 as white foam. 
1H NMR (DMSO-d6): 10.64 [bs, 1H, H-1]; 7.89 [s, 1H, 
H-8]; 6.48 [bs, 2H, NH2]; 4.60 [m, 1H, H-1’]; 3.89-3.96 
[m, 8H, CH2CH3]; 3.82 [dd, 2H, J(gem) = 10.4 Hz, 
J(2’a,1’) = 6.9 Hz, H-2’a]; 3.72 [dd, 2H, J(gem) = 10.4 
Hz, J(2’b,1’) = 5.0 Hz, H-2’b]; 3.50-3.62 [m, 4H, 
CH2CH2-P]; 1.97-2.04 [m, 4H, CH2-P]; 1.19 and 1.18 [t, 
12H, J(CH3,CH2) = 7.1 Hz, CH3]. 13C NMR (DMSO-d6): 156.75 [C-6]; 153.75 [C-2]; 151.34 
[C-4]; 136.55 [C-8]; 115.77 [C-5]; 68.80 [C-2’]; 64.89 [d, J(C,C,P) = 1.5 Hz, CH2CH2-P]; 
61.13-61.19 [m, CH2CH3]; 53.42 [C-1’]; 25.94 [d, J(C,P) = 136.9 Hz, CH2-P]; 16.41 [d, 
J(C,C,O,P) = 5.8 Hz, CH3]. MS (ESI+) m/z = 554.3 [M + H]+. 
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Tetraethyl {[(2-(hypoxanthine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (13) 
From compound 9 (3.0 g, 5.38 mmol) according to Method C, afforded 2.0 g (69%) of 13 as 
white foam. 
1H NMR (DMSO-d6): 12.43 [bs, 1H, H-1]; 8.37 [s, 1H, 
H-8]; 8.08 [bs, 1H, H-2]; 4.86 [m, 1H, H-1’]; 3.87-3.95 
[m, 10H, H-2’a, CH2CH3]; 3.79 [dd, 2H, J(gem) = 10.6 
Hz, J(2’b,1’) = 4.8 Hz, H-2’b]; 3.51-3.62 [m, 4H, 
CH2CH2-P]; 1.94-2.04 [m, 4H, CH2-P]; 1.16-1.19 [m, 
12H, CH3]. 13C NMR (DMSO-d6): 156.39 [C-6]; 148.53 
[C-4]; 146.08 [C-2]; 139.59 [C-8]; 122.83 [C-5]; 68.75 [C-2’]; 64.87 [d, J(C,C,P) = 1.8 Hz, 
CH2CH2-P]; 61.11-61.18 [m, CH2CH3]; 54.42 [C-1’]; 25.91 [d, J(C,P) = 137.2 Hz, CH2-P]; 
16.40 and 16.40 [d, J(C,C,O,P) = 5.8 Hz, CH3]. MS (ESI+) m/z = 539.3 [M + H]+. 
 
Tetraethyl {[(2-(8-bromoguanine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (14) 
From compound 12 (1 g, 1.8 mmol) according to Method F, afforded 685 mg (60%) of 14 as 
yellowish solidified oil. 
1H NMR (DMSO-d6): 10.57 [bs, 1H, H-1]; 6.40 [bs, 2H, 
NH2]; 4.69 [m, 1H, H-1’]; 4.09 [dd, 2H, J(gem) = 10.5 
Hz, J(2’a,1’) = 8.8 Hz, H-2’a]; 3.90-3.97 [m, 8H, 
CH2CH3]; 3.81 [dd, 2H, J(gem) = 10.5 Hz, J(2’b,1’) = 
5.4 Hz, H-2’b]; 3.50-3.65 [m, 4H, H-3’]; 1.92-1.98 [m, 
4H, H-4’]; 1.18-1.22 [m, 12H, CH3]. 13C NMR (DMSO-
d6): 155.35 [C-6]; 153.17 [C-2]; 152.36 [C-4]; 121.38 [C-8]; 117.26 [C-5]; 67.21 [C-2’]; 
64.54 [d, J(C,C,P) = 1.2 Hz, C-3’]; 60.84-60.90 [m, CH2CH3]; 57.10 [C-1’]; 26.04 [d, J(C,P) 
= 137.2 Hz, C-4’]; 16.03 and 16.02 [d, J(C,C,O,P) = 5.7 Hz, CH3]. MS (ESI+) m/z = 632.4 
[M + H]+. 
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Tetraethyl {[(2-(8-bromohypoxanthine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (15) 
From compound 13 (659 mg, 1.22 mmol) according to Method F, afforded 305 mg (49%) of 
15 as yellowish solid. 
1H NMR (DMSO-d6): 12.35 [bs, 1H, H-1]; 8.01 [s, 1H, 
H-2]; 4.87 [m, 1H, H-1’]; 4.12 [dd, 2H, J(gem) = 10.6 Hz, 
J(2’a,1’) = 9.0 Hz, H-2’a]; 3.84-3.95 [m, 10H, H-2’b, 
CH2CH3]; 3.48-3.65 [m, 4H, CH2CH2-P]; 1.93 [dt, 4H, 
J(H,C,P) = 18.3 Hz, J(CH2,CH2) = 7.2 Hz, CH2-P]; 1.19 
and 1.18 [t, 12H, J(CH3,CH2) = 7.1 Hz, CH3]. 13C NMR 
(DMSO-d6): 155.21 [C-6]; 149.68 [C-4]; 145.58 [C-2]; 126.11 [C-8]; 124.79 [C-5]; 67.32 [C-
2’]; 64.64 [d, J(C,C,P) = 1.4 Hz, CH2CH2-P]; 60.86-60.93 [m, CH2CH3]; 58.06 [C-1’]; 25.99 
[d, J(C,P) = 137.3 Hz, CH2-P]; 16.10 and 16.08 [d, J(C,C,O,P) = 5.7 Hz, CH3]. MS (ESI+) 
m/z = 617.2 [M + H]+. 
 
Tetraethyl {[(2-(7-deaguanine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (16) 
From compound 10 (2.49 g, 4.36 mmol) according to Method D, afforded 414 mg (17%) of 
16 as white solid. 
1H NMR (DMSO-d6): 10.29 [bs, 1H, H-1]; 6.86 [d, 1H, 
J(8,7) = 3.6 Hz, H-8]; 6.21 [d, 1H, J(7,8) = 3.6 Hz, H-7]; 
6.17 [bs, 2H, NH2]; 4.73 [m, 1H, H-1’]; 3.89-3.96 [m, 8H, 
CH2CH3]; 3.66-3.73 [m, 4H, H-2’]; 3.48-3.60 [m, 4H, 
CH2CH2-P]; 1.93-2.06 [m, 4H, CH2-P]; 1.19 and 1.18 [t, 
12H, J(CH3,CH2) = 7.1 Hz, CH2CH3]. 13C NMR (DMSO-
d6): 158.90 [C-6]; 152.43 [C-2]; 150.64 [C-4]; 118.37 [C-8]; 101.49 [C-7]; 99.93 [C-5]; 69.58 
[C-2’]; 64.84 [d, J(C,C,P) = 1.5 Hz, CH2CH2-P]; 61.14-61.19 [m, CH2CH3]; 52.85 [C-1’]; 
26.03 [d, J(C,P) = 136.9 Hz, CH2-P]; 16.42 [d, J(C,C,O,P) = 5.8 Hz, CH3]. MS (ESI+) m/z = 
552.9 [M + H]+. 
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Tetraethyl {[(2-(7-deazahypoxanthine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}bis(phosphonate) (17) 
From compound 11 (3.5 g, 6.3 mmol) according to Method D, afforded 847 mg (25%) of 17 
as white solid. 
1H NMR (DMSO-d6): 11.86 [bs, 1H, H-1]; 7.87 [d, 1H, 
J(2,1) = 2.4 Hz, H-2]; 7.28 [d, 1H, J(8,7) = 3.5 Hz, H-8]; 
6.47 [d, 1H, J(7,8) = 3.5 Hz, H-7]; 4.95 [m, 1H, H-1’]; 
3.87-3.95 [m, 8H, CH2CH3]; 3.80 [dd, 2H, J(gem) = 10.5 
Hz, J(2’a,1’) = 7.2 Hz, H-2’a]; 3.74 [dd, 2H, J(gem) = 
10.5 Hz, J(2’b,1’) = 5.0 Hz, H-2’b]; 3.48-3.61 [m, 4H, 
CH2CH2-P]; 1.91-2.04 [m, 4H, CH2-P]; 1.18 and 1.17 [t, 12H, J(CH3,CH2) = 7.1 Hz, CH3]. 
13C NMR (DMSO-d6): 158.44 [C-6]; 147.63 [C-4]; 143.99 [C-2]; 122.09 [C-8]; 107.86 [C-5]; 
101.81 [C-7]; 69.55 [C-2’]; 64.80 [d, J(C,C,P) = 1.5 Hz, CH2CH2-P]; 61.08-61.15 [m, 
CH2CH3]; 53.66 [C-1’]; 25.99 [d, J(C,P) = 137.0 Hz, CH2-P]; 16.40 and 16.40 [d, J(C,C,O,P) 
= 5.8 Hz, CH3]. MS (ESI+) m/z = 538.2 [M + H]+. 
 
 
 
Sodium salt of {[(2-(guanine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}diphosphonic acid (18) 
From compound 12 (475 mg, 0.85 mmol) according to Method E, afforded 68 mg (15%) of 
18 as white lyophilisate. 
1H NMR (D2O): 8.17 [s, 1H, H-8]; 4.84 [m, 1H, H-1’]; 4.01 
[dd, 2H, J(gem) = 11.1 Hz, J(2’a,1’) = 7.7 Hz, H-2’a]; 3.91 
[dd, 2H, J(gem) = 11.1 Hz, J(2’b,1’) = 4.4 Hz, H-2’b]; 
3.64-3.79 [m, 4H, CH2CH2-P]; 1.81-1.95 [m, 4H, CH2-P]. 
13C NMR (D2O): 159.26 [C-6]; 154.61 [C-2]; 152.57 [C-4]; 
139.25 [C-8]; 115.37 [C-5]; 69.24 [C-2’]; 67.48 [d, J(C,C,P) = 1.5 Hz, CH2CH2-P]; 54.81 [C-
1’]; 29.35 [d, J(C,P) = 129.8, CH2-P]. HR-MS (ESI-) m/z: calcd for 
C12H17N5Na4O9P2 440.07417 [M – 4 Na + 3 H]-, found 440.07418 [M – 4 Na + 3 H]-. 
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Sodium salt of {[(2-(hypoxanthine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}diphosphonic acid (19) 
The 6-chloropurine derivative 9 (1.2 g, 2.15 mmol) was placed into 10 ml MW reactor cuvette 
and aqueous HCl (6 ml of 1.4 M) was added. Cuvette was sealed with a septum and reaction 
mixture was stirred in MW reactor at 140 °C for 2 hours. The mixture was neutralized by 
aqueous NH3 (conc. 36%) and evaporated in vacuo. The residue was subsequently dissolved 
in solution of TEAB and processed identically that described above in Method E, afforded 
317 mg (35%) of 19 as white lyophilisate. 
1H NMR (D2O): 8.34 [s, 1H, H-8]; 8.20 [s, 1H, H-2]; 5.04 
[m, 1H, H-1’]; 4.08 [dd, 2H, J(gem) = 11.1 Hz, J(2’a,1’) = 
7.9 Hz, H-2’a]; 3.97 [dd, 2H, J(gem) = 11.1 Hz, J(2’b,1’) = 
4.4 Hz, H-2’b]; 3.63-3.77 [m, 4H, H-3’]; 1.76-1.89 [m, 4H, 
H-4’]. 13C NMR (D2O): 159.41 [C-6]; 149.98 [C-4]; 146.34 
[C-2]; 141.89 [C-8]; 123.95 [C-5]; 69.23 [C-2’]; 67.80 [d, J(C,C,P) = 1.9 Hz, C-3’]; 55.75 [C-
1’]; 29.55 [d, J(C,P) = 129.0 Hz, C-4’]. HR-MS (ESI-) m/z: calcd for 
C12H16N4Na4O9P2 425.06327 [M – 4 Na + 3 H]-, found 425.06334 [M – 4 Na + 3 H]-. 
 
Sodium salt of {[(2-(8-bromoguanine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}diphosphonic acid (20) 
From compound 14 (340 mg, 0.54 mmol) according to Method E, afforded 82 mg (27%) of 
20 as white lyophilisate. 
1H NMR (DMSO-d6): 5.01 [m, 1H, H-1’]; 4.30 [dd, 2H, 
J(gem) = 11.2 Hz, J(2’a,1’) = 9.7 Hz, H-2’a]; 3.89 [dd, 2H, 
J(gem) = 11.2 Hz, J(2’b,1’) = 4.7 Hz, H-2’b]; 3.74-3.80 
and 3.63-3.68 [m, 4H, H-3’]; 1.75-1.87 [m, 4H, H-4’]. 13C 
NMR (DMSO-d6): 158.70 [C-6]; 154.01 [C-2]; 117.63 [C-
5]; 67.85 [d, J(C,C,P) = 2.6 Hz, C-3’]; 67.52 [C-2’]; 58.3 [C-1’]; 29.76 [d, J(C,P) = 128.1 Hz, 
C-4’]. HR-MS (ESI-): calcd for C12H16BrN5Na4O9P2 539.96663 [M – 3 Na + 2 H]-, found 
539.96632 [M – 3 Na + 2 H]-. 
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Sodium salt of {[(2-(8-bromohypoxanthine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-
2,1-diyl)}diphosphonic acid (21) 
From compound 15 (285 mg, 0.46 mmol) according to Method E, afforded 27 mg (10%) of 
21 as yellowish lyophilisate. 
1H NMR (D2O): 8.14 [s, 1H, H-2]; 5.19 [m, 1H, H-1’]; 4.32 
[dd, 2H, J(gem) = 11.2 Hz, J(2’a,1’) = 9.7 Hz, H-2’a]; 3.96 
[dd, 2H, J(gem) = 11.2 Hz, J(2’b,1’) = 4.7 Hz, H-2’b]; 
3.59-3.80 [m, 4H, CH2CH2-P]; 1.73-1.86 [m, 4H, CH2-P]. 
13C NMR (D2O): 158.14 [C-6]; 150.92 [C-4]; 146.14 [C-2]; 
125.10 [C-5]; 67.72 [d, J(C,C,P) = 2.3 Hz, CH2CH2-P]; 67.64 [C-2’]; 59.1 [C-1’]; 29.56 [d, 
J(C,P) = 128.6 Hz, CH2-P]. HR-MS (ESI-) m/z: calcd for C12H15BrN4Na4O9P2 502.97379 [M 
– 4 Na + 3 H]-, found 502.97395 [M – 4 Na + 3 H]-. 
 
Sodium salt of {[(2-(7-deazaguanine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}diphosphonic acid (22) 
From compound 16 (134 mg, 0.24 mmol) according to Method E, afforded 51 mg (48%) of 
22 as white lyophilisate. 
1H NMR (D2O): 7.05 [d, 1H, J(8,7) = 3.7 Hz, H-8]; 6.54 [d, 
1H, J(7,8) = 3.7 Hz, H-7]; 4.94 [m, 1H, H-1’]; 3.91 [dd, 2H, 
J(gem) = 11.1 Hz, J(2’a,1’) = 8.2 Hz, H-2’a]; 3.85 [dd, 2H, 
J(gem) = 11.1 Hz, J(2’b,1’) = 4.7 Hz, H-2’b]; 3.62-3.77 [m, 
4H, H-3’]; 1.77-1.91 [m, 4H, H-4’]. 13C NMR (D2O): 
162.20 [C-6]; 153.06 [C-2]; 152.31 [C-4]; 120.45 [C-8]; 102.60 [C-7]; 100.55 [C-5]; 69.81 
[C-2’]; 67.55 [d, J(C,C,P) = 2.0 Hz, C-3’]; 53.88 [C-1’]; 29.51 [d, J(C,P) = 128.9 Hz, C-4’]. 
HR-MS (ESI-) m/z: calcd for C13H18N4Na4O9P2 439.07892 [M – 4 Na + 3 H]-, found 
439.07907 [M – 4 Na + 3 H]-. 
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Sodium salt of {[(2-(7-deazahypoxanthine-9-yl)propane-1,3-diyl)bis(oxy)]bis(ethane-2,1-
diyl)}diphosphonic acid (23) 
From compound 17 (447 mg, 0.83 mmol) according to Method E, afforded 179 mg (42%) of 
23 as white lyophilisate. 
1H NMR (D2O): 8.07 [s, 1H, H-2]; 7.40 [d, 1H, J(8,7) = 3.6 
Hz, H-8]; 6.76 [d, 1H, J(7,8) = 3.6 Hz, H-7]; 5.13 [m, 1H, 
H-1’]; 3.99 [dd, 2H, J(gem) = 11.2 Hz, J(2’a,1’) = 8.4 Hz, 
H-2’a]; 3.91 [dd, 2H, J(gem) = 11.2 Hz, J(2’b,1’) = 4.5 Hz, 
H-2’b]; 3.60-3.74 [m, 4H, CH2CH2-P]; 1.75-1.89 [m, 4H, 
CH2-P]. 13C NMR (D2O): 161.60 [C-6]; 149.17 [C-4]; 143.70 [C-2]; 123.65 [C-8]; 108.23 [C-
5]; 103.01 [C-7]; 69.71 [C-2’]; 67.34 [d, J(C,C,P) = 1.9 Hz, CH2CH2-P]; 54.83 [C-1’]; 29.29 
[d, J(C,P) = 129.5 Hz, CH2-P]. HR-MS (ESI-) m/z: calcd for C13H17N3Na4O9P2 424.06803 [M 
– 4 Na + 3 H]-, found 424.06813 [M – 4 Na + 3 H]-. 
5-Hydroxymethyl-2,2-dimethyl-1,3-dioxane (24) 
To a solution of 2-hydroxymethyl-1,3-propanediol (20 g, 189 mmol) in dry acetone (600 ml) 
freshly annealed molecular sieves (4Å) and p-toluenesulfonic acid monohydrate (2 g, 10.5 
mmol) were added. Reaction mixture was stirred overnight at room temperature. Mixture was 
filtered over kieselguhr. To the filtrate DOWEX (D1 OH-, 7 g) was added and the mixture 
was heated to 40 °C and stirred for 30 min. Suspension was filtered over frit (S3) and Et3N 
(0.5 ml) was added to the filtrate for stabilization. Solvent was evaporated in vacuo and 
obtained crude material was dried under vacuum. Crude product 24 was obtained as 
colourless oil and used in the next reaction step without purification. Reaction was monitored 
by TLC (Procedure 5). 
 
2-(Benzyloxymethyl)propane-1,3-diol (26) 
To a solution of compound 24 (crude material ~ max. 94 mmol) in dry DMF (600 ml) cooled 
to 0°C under argon atmosphere and NaH (60% suspension in mineral oil; 6 g, 150 mmol,  1.6 
eq.) was added. Reaction flask was filled with argon again and the mixture was stirred for 20 
min. to preform sodium salt of alcohol. Benzyl bromide (14.6 ml, 123 mmol, 1.3 eq.) was 
added and reaction flask was filled with argon again. The resulting mixture was let to warm to 
  
 30 
room temperature and stirred overnight. Water (100 ml) was added and mixture was stirred 
for 30 min. Solvent was evaporated in vacuo and the residue was codistilled with toluene (3x). 
Crude material was suspended in EtOAc (250 ml) and mixture of saturated solution of NH4Cl 
(20 ml) and water (180 ml) was added. Water phase was extracted with EtOAc (2x 150 ml). 
The organic phase was collected (250+150+150 ml) and washed with water (2x 200 ml), 
followed by brine (1x 200ml) and dried over MgSO4. The solution was filtered and 
evaporated in vacuo. The residue (crude compound 25, red-brown oil) was diluted in MeOH 
(700 ml) and water (70 ml). DOWEX (50WX8 H+, 30 g) was added and the mixture was 
heated at 50 °C and stirred overnight. Reaction mixture was cooled down to room temperature 
and filtered through the frit (S3), evaporated in vacuo and codistilled with toluene (3x). Crude 
product 26 was obtained as brown oil and used in the next reaction step without purification. 
Reaction was monitored by TLC (Procedure 5). Small amount of crude product was purified 
by flash chromatography (silica gel; eluent CHCl3/MeOH, gradient 2-15%) to obtain an 
analytical sample. 
1H NMR (DMSO-d6): 7.25-7.36 [m, 5H, H-2, H-3, H-4]; 4.44 [s, 2H, 1-
CH2]; 4.40 [bs, 2H, OH]; 3.46 [d, 4H, J(CH2,CH) = 6.0 Hz, CH2-OH]; 3.44 
[d, 2H, J(CH2,CH) = 6.1 Hz, 1-CH2O-CH2]; 1.82 [septet, J(CH,CH2) = 6.0 
Hz, CHCH2-OH]. 13C NMR (DMSO-d6): 139.02 [C-1]; 128.44 [C-3]; 
127.55 [C-2]; 127.51 [C-4]; 72.40 [1-CH2]; 68.80 [1-CH2O-CH2]; 59.75 
[CH2-OH]; 44.60 [CHCH2-OH]. 
 
Tetraethyl {[(2-(benzyloxymethyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (27) 
From comopund 26 (crude material ~ max. 94 mmol) according to procedure for preparation 
of compound 6. Crude product was obtained as brown oil and used in the next reaction step 
without purification. Part of the crude product was purified by flash chromatography (silica 
gel; eluent hexane:EtOAc [6:4]/MeOH, gradient 1-10 %) for determining the NMR spectra. 
1H NMR (DMSO-d6): 7.26-7.42 [m, 5H, H-2’, H-3’, H-4’]; 
4.44 [s, 2H, CH2Ph]; 3.93-4.00 [m, 8H, CH2CH3]; 3.53 [dt, 4H, 
J(2,P) = 13.3 Hz, J(2,1) = 7.2 Hz, H-2]; 3.43 [d, 2H, J(5,4) = 
6.0 Hz, H-5]; 3.40 [d, 4H, J(3,4) = 6.0 Hz, H-3]; 1.98-2.07 [m, 
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5H, H-1, H-4]; 1.21 [t, 12H, J(CH3,CH2) = 7.1 Hz, CH3]. 13C NMR (DMSO-d6): 138.77 [C-
1’]; 128.41 [C-3’]; 127.55 [C-4’]; 127.53 [C-2’]; 72.32 [CH2Ph]; 68.62 [C-3]; 68.16 [C-5]; 
64.72 [d, J(2,P) = 1.6 Hz, C-2]; 61.11 [d, J(C,O,P) = 6.2 Hz, CH2CH3]; 39.96 [C-4]; 26.07 [d, 
J(1,P) = 137.0 Hz, C-1]; 16.44 [d, J(C,C,O,P) = 5.9 Hz, CH3]. MS (ESI+) m/z = 525.2 [M + 
H]+. 
 
Tetraethyl {[(2-(hydroxymethyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (28) 
From crude material 27 according to procedure for preparation of compound 7, afforded 19.8 
g (5-steps overall yield from 2-hydroxymethyl-1,3-
propanediol: 48%) of 28 as colourless oil. 
1H NMR (DMSO-d6): 4.44 [bt, 1H, J(OH,1) = 5.4 Hz, OH]; 
3.93-4.03 [m, 8H, CH2CH3]; 3.53 [dt, 4H, J(H,C,C,P) = 13.5 
Hz, J(CH2,CH2) = 7.3 Hz, CH2CH2-P]; 3.34-3.41 [m, 6H, H-1, 
H-3]; 2.03 [dt, 4H, J(H,C,P) = 18.2 Hz, J(CH2,CH2) = 7.2 Hz, 
CH2-P]; 1.85 [septet, 1H, J(2,1) = J(2,3) = 6.0 Hz, H-2]; 1.22 [t, 12H, J(CH3,CH2) = 7.1 Hz, 
CH3]. 13C NMR (DMSO-d6): 68.72 [C-3]; 64.65 [d, J(C,C,P) = 1.8 Hz, CH2CH2-P]; 61.14 [d, 
J(C,O,P) = 6.1 Hz, CH2CH3]; 59.36 [C-1]; 42.11 [C-2]; 26.07 [d, J(C,P) = 137.0 Hz, CH2-P]; 
16.44 [d, J(C,C,O,P) = 5.9 Hz, CH3]. MS (ESI+) m/z = 434.9  [M + H]+. 
 
Tetraethyl {[(2-((2-amino-6-chloro-purin-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (29) 
From compound 28 (2.5 g, 5.76 mmol) according to Method B, afforded 2.13 g (63%) of 29 
as colourless solidified oil. 
1H NMR (DMSO-d6): 8.11 [s, 1H, H-8]; 6.91 [bs, 2H, 
NH2]; 4.09 [d, 2H, J(1’,2’) = 7.0 Hz, H-1’]; 3.94-4.01 [m, 
8H, CH2CH3]; 3.46-3.57 [m, 4H, CH2CH2-P]; 3.30-3.36 
[m, 4H, H-3’]; 2.41 [m, H-2’] ; 2.02 [dt, 4H, J(H,C,P) = 
18.2 Hz, J(CH2,CH2) = 7.2 Hz, CH2-P]; 1.21 [t, 12H, 
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J(CH3,CH2) = 7.0 Hz, CH3]. 13C NMR (DMSO-d6): 159.96 [C-2]; 154.59 [C-4]; 149.43 [C-6]; 
144.08 [C-8]; 123.49 [C-5]; 68.63 [C-3’]; 64.67 [d, J(C,C,P) = 1.7 Hz, CH2CH2-P]; 61.16-
61.22 [m, CH2CH3]; 42.47 [C-1’]; 38.84 [C-2’]; 25.88 [d, J(C,P) = 137.1 Hz, CH2-P]; 16.44 
[d, J(C,C,O,P) = 5.9 Hz, CH3]. MS (ESI+) m/z = 586.0 [M + H]+. 
 
Tetraethyl {[(2-((6-chloropurin-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (30) 
From compound 28 (3 g, 6.9 mmol) according to method A, afforded 2.4 g (61%) of 30 as 
yellowish solid. 
1H NMR (DMSO-d6): 8.76 [s, 1H, H-2]; 8.71 [s, 1H, H-8]; 
4.36 [d, 2H, J(1’,2’) = 7.0 Hz, H-1’]; 3.92-4.01 [m, 8H, 
CH2CH3]; 3.44-3.50 [m, 4H, CH2CH2-P]; 3.35-3.39 [m, 4H, 
H-3’]; 2.49 [m, 1H, H-2’]; 1.96 [dt, 4H, J(H,C,P) = 18.2 Hz, 
J(CH2,CH2) = 7.2 Hz, CH2-P]; 1.21 and 1.21 [t, 12H, 
J(CH3,CH2) = 7.1 Hz, CH3]. 13C NMR (DMSO-d6): 152.50 
[C-4]; 151.57 [C-2]; 149.06 [C-6]; 148.35 [C-8]; 131.03 [C-
5]; 68.86 [C-3’]; 64.71 [d, J(C,C,P) = 1.6 Hz, CH2CH2-P]; 61.13-61.19 [m, CH2CH3]; 43.62 
[C-1’]; 39.08 [C-2’]; 25.85 [d, J(C,P) = 137.2 Hz, CH2-P]; 16.43 [d, J(C,C,O,P) = 5.9 Hz, 
CH3]. MS (ESI+) m/z = 572.1 [M + H]+. 
 
Tetraethyl {[(2-((2-amino-6-chloro-7-deazapurin-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (31) 
From compound 28 (4.4 g, 10 mmol) according to Method B, afforded 1.69 g (29%) of 31 as 
yellowish solid. 
1H NMR (DMSO-d6): 7.17 [s, 1H, J(8,7) = 3.6 Hz, H-8]; 
6.67 [bs, 2H, NH2]; 6.28 [d, 1H, J(7,8) = 3.6 Hz, H-7]; 
4.05 [d, 2H, J(1’,2’) = 7.1 Hz, H-1’]; 3.94-4.01 [m, 8H, 
CH2CH3]; 3.46-3.57 [m, 4H, CH2CH2-P]; 3.26-3.32 [m, 
4H, H-3’]; 2.36 [m, 1H, H-2’]; 2.03 [dt, 4H, J(H,C,P) = 
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18.2 Hz, J(CH2,CH3) = 7.1 Hz, CH2-P]; 1.21 [t, 12H, J(CH3,CH2) = 7.1 Hz, CH3]. 13C NMR 
(DMSO-d6): 159.50 [C-2]; 153.89 [C-4]; 151.26 [C-6]; 127.37 [C-8]; 108.77 [C-5]; 98.48 [C-
7]; 68.57 [C-3’]; 64.69 [d, J(C,C,P) = 1.7 Hz, CH2CH2-P]; 61.20 and 61.19 [d, J(C,O,P) = 6.2 
Hz and J(C,O,P) = 6.2 Hz, CH2CH3]; 43.19 [C-1’]; 39.45 [C-2’]; 25.91 [d, J(C,P) = 137.3 Hz, 
CH2-P]; 16.48 [d, J(C,C,O,P) = 5.9 Hz, CH3]. MS (ESI+) m/z = 585.2 [M + H]+. 
 
Tetraethyl {[(2-((6-chloro-7-deazapurin-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (32) 
From compound 28 (3 g, 6.9 mmol) according to Method A, afforded 2.45 g (62%) of 32 as 
yellowish solid. Presence of product was confirmed by LC-MS (procedure 1). Pure product 
was used in the next reaction step without additional characterisation. MS (ESI+) m/z = 570.2 
[M + H]+. 
 
Tetraethyl {[(2-((guanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (33) 
From compound 29 (1.56 g, 2.67 mmol) according to Method C, afforded 1.45 g (96 %) of 
33 as white foam. 
1H NMR (DMSO-d6): 10.64 [s, 1H, NH]; 7.78 [s, 1H, H-
8]; 6.52 [bs, 2H, NH2]; 3.94-4.02 [m, 10H, H-1’, 
CH2CH3]; 3.47-3.58 [m, 4H, H-4’]; 3.28-3.34 [m, 4H, H-
3’]; 2.35 [m, 1H, H-2’]; 2.04 [dm, 4H, J(5’,P) = 18.4 Hz, 
H-5’]; 1.22 [t, 12H, J(CH3,CH2) = 7.1 Hz, CH2CH3]. 13C 
NMR (DMSO-d6): 156.75 [C-6]; 153.84 [C-2]; 151.51 
[C-4]; 138.28 [C-8]; 115.98 [C-5]; 68.49 [C-3’]; 64.66 [d, 
J(4’,P) = 1.8 Hz, C-4’]; 61.22 and 61.21 [d, J(C,O,P) = 6.2 Hz, CH2CH3]; 42.13 [C-1’]; 39.12 
[C-2’]; 25.91 [d, J(5’,P) = 137.1 Hz, C-5’]; 16.44 d, J(C,C,O,P) = 5.9 Hz, CH3]. MS (ESI+) 
m/z = 568.2 [M + H]+. 
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Tetraethyl {[(2-((hypoxanthine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (34) 
From compound 30 (2.4 g, 4.2 mmol) according to Method C, afforded 905 mg (38%) of 34 
as yellowish foam. 
1H NMR (DMSO-d6): 12.27 [bs, 1H, NH]; 8.07 [s, 1H, H-8]; 
8.01 [s, 1H, H-2]; 4.18 [d, 2H, J(1’,2’) = 7.1 Hz, H-1’]; 3.92-
4.02 [m, 8H, CH2CH3]; 3.46-3.52 [m, 4H, H-4’];  3.27-3.36 
[m, 4H, H-3’]; 2.39 [m, 1H, H-2’]; 2.01 [dm, 4H,  J(5’,P) = 
18.1 Hz, H-5’]; 1.21 [t, 12H, J(CH3,CH2) = 7.2 Hz, 
CH2CH3]. 13C NMR (DMSO-d6): 156.94 [C-6]; 148.84 [C-
4]; 145.62 [C-2]; 141.18 [C-8]; 124.12 [C-5]; 68.68 [C-3’]; 
64.77 [d, J(4’,P) = 1.9 Hz, C-4’]; 61.21 and 61.19 [d, J(C,O,P) = 6.2 Hz, CH2CH3]; 42.88 [C-
1’]; 39.50 [C-2’]; 25.90 [d, J(5’,P) = 137.1 Hz, C-5’]; 16.47 [d, J(C,C,O,P) = 5.9 Hz, 
CH2CH3]. MS (ESI+) m/z = 553.3 [M + H]+. 
 
Tetraethyl {[(2-((8-bromoguanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (35) 
From compound 33 (289 mg, 0.5 mmol) according to Method F, afforded 311 mg (96 %) of 
35 as yellowish solid. 
1H NMR (DMSO-d6): 10.68 [bs, 1H, NH]; 6.61 [bs, 2H, 
NH2]; 3.91-4.02 [m, 10H, H-1’, CH2CH3]; 3.42-3.59 [m, 
4H, H-4’]; 3.32-3.39 [m, 4H, H-3’]; 2.41 [m, 1H, H-2’]; 
2.00 [dm, 4H, J(5’,P) = 18.2 Hz, H-5’]; 1.21 [t, 12H, 
J(CH3,CH2) = 7.1 Hz, CH2CH3]. 13C NMR (DMSO-d6): 
155.79 [C-6]; 153.99 [C-2]; 152.98 [C-4]; 121.48 [C-8]; 
116.94 [C-5]; 68.86 [C-3’]; 64.62 [d, J(4’,P) = 1.1 Hz, C-
4’]; 61.27 and 61.23 [d, J(C,O,P) = 6.1 Hz, CH2CH3]; 43.56 [C-1’]; 38.76 [C-2’]; 25.91 [d, 
J(5’,P) = 136.9 Hz, C-5’]; 16.47 [d, J(C,C,O,P) = 5.9 Hz, CH3]. MS (ESI+) m/z = 646.4 [M + 
H]+. 
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Tetraethyl {[(2-((8-bromohypoxanthine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (36) 
From compound 34 (540 mg, 0.98 mmol) according to Method F, afforded 435 mg (70%) of 
36 as yellowish solid. Pure product was used in the next reaction step without additional 
characterisation. MS (ESI+) m/z = 631.2 [M + H]+. 
 
Tetraethyl {[(2-((7-deazaguanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (37) 
From compound 31 (1.69 g, 2.89 mmol) according to Method D, afforded 802 mg (49%) of 
37 as white foam. 
1H NMR (DMSO-d6): 10.30 [bs, 1H, H-1]; 6.70 [d, 1H, 
J(8,7) = 3.4 Hz, H-8]; 6.23 [bs, 2H, NH2]; 6.20 [d, J(7,8) 
= 3.4 Hz, H-7]; 3.94-4.02 [m, 8H, CH2CH3]; 3.92 [d, 2H, 
J(1’,2’) = 7.2 Hz, H-1’]; 3.46-3.58 [m, 4H, CH2CH2-P]; 
3.25-3.31 [m, 4H, H-3’]; 2.29 [m, 1H, H-2’]; 2.04 [dt, 2H, 
J(H,C,P) = 18.2 Hz, J(CH2,CH3) = 7.1 Hz, CH2-P]; 1.22 
[t, 12H, J(CH3,CH2) = 7.1 Hz, CH3]. 13C NMR (DMSO-
d6): 158.90 [C-6]; 152.53 [C-2]; 150.62 [C-4]; 121.09 [C-8]; 101.22 [C-7]; 100.06 [C-5]; 
68.51 [C-3’]; 64.67 [d, J(C,C,P) = 1.7 Hz, CH2CH2-P]; 61.21 and 61.20 [d, J(C,O,P) = 6.2 
Hz, CH2CH3]; 43.00 [C-1’]; 39.85 [C-2’]; 25.95 [d, J(C,P) = 136.8 Hz, CH2-P]; 16.48 [d, 
J(C,C,O,P) = 5.9 Hz, CH3]. MS (ESI+) m/z = 567.3 [M + H]+. 
 
Tetraethyl {[(2-((7-deazahypoxanthine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}bis(phosphonate) (38) 
From compound 32 (2.45 g, 4.3 mmol) according to Method D, afforded 1.18 g (50%) of 38 
as white foam. 
1H NMR (DMSO-d6): 11.90 [bs, 1H, H-1]; 7.87 [s, 1H, H-2]; 
7.15 [d, 1H, J(8,7) = 3.4 Hz, H-8]; 6.45 [d, 1H, J(7,8) = 3.4 
Hz, H-7]; 4.15 [d, 2H, J(1’,2’) = 7.2 Hz, H-1’]; 3.92-4.02 [m, 
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8H, CH2CH3]; 3.49 [dt, 4H, J(H,C,C,P) = 13.7 Hz, J(CH2,CH2) = 7.2 Hz, CH2CH2-P]; 3.27-
3.32 [m, 4H, H-3’]; 2.34 [m, 1H, H-2’]; 1.98-2.08 [m, 4H, CH2-P]; 1.21 [t, 12H, J(CH3,CH2) 
= 7.1 Hz, CH3]. 13C NMR (DMSO-d6): 158.51 [C-6]; 147.52 [C-4]; 143.52 [C-2]; 124.72 [C-
8]; 107.99 [C-5]; 101.55 [C-7]; 68.65 [C-3’]; 64.80 [d, J(C,C,P) = 1.6 Hz, CH2CH2-P]; 61.16-
61.22 [m, CH2CH3]; 43.86 [C-1’]; 25.93 [d, J(C,P) = 137.0 Hz, CH2-P]; 16.51 [d, J(C,C,O,P) 
= 5.9 Hz, CH3]. MS (ESI+) m/z = 552.2 [M + H]+. 
 
Sodium salt of {[(2-((guanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (39) 
From compound 33 (513 mg, 0.9 mmol) according to Method E, afforded 87 mg (18 %) of 
39 as yellowish lyophilisate. 
1H NMR (D2O): 8.12 [s, 1H, H-8]; 4.22 [d, 2H, J(1’,2’) = 
6.7 Hz, H-1’]; 3.60-3.70 [m, 4H, H-4’]; 3.47-3.53 [m, 4H, 
H-3’]; 2.51 [m, 1H, H-2’]; 1.86-1.94 [m, 4H, H-5’]. 13C 
NMR (D2O): 158.50 [C-6]; 154.70 [C-2]; 152.09 [C-4]; 
140.58 [C-8]; 114.16 [C-5]; 69.47 [C-3’]; 67.06 [C-4’]; 
44.08 [C-1’]; 39.39 [C-2’]; 29.28 [d, J(5’,P) = 130.2 Hz, 
C-5’]. HR-MS (ESI-): calcd for C13H19N5Na4O9P2 
476.07177 [M – 3 Na + 2 H]-, found 476.07204 [M – 3 Na + 2 H]-. 
 
Sodium salt of {[(2-((hypoxanthine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (40) 
From compound 34 (447 mg, 0.8 mmol) according to Method E, afforded 155 mg (37%) of 
40 as white lyophilisate. 
1H NMR (D2O): 8.21 [s, 1H, H-2]; 8.15 [s, 1H, H-8]; 4.38 [d, 
2H, J(1’,2’) = 6.9 Hz, H-1’]; 3.57-3.65 [m, 4H, H-4’]; 3.49-
3.55 [m, 4H, H-3’]; 2.54 [m, 1H, H-2’]; 1.82-1.89 [m, 4H, H-
5’]. 13C NMR (D2O): 159.28 [C-6]; 149.94 [C-4]; 146.33 [C-
2]; 143.45 [C-8]; 123.79 [C-5]; 69.58 [C-3’]; 67.18 [d, J(4’,P) 
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= 1.8 Hz, C-4’]; 44.36 [C-1’]; 39.85 [C-2’]; 29.31 [d, J(5’,P) = 129.8 Hz, C-5’]. HR-MS 
(ESI+) m/z: calcd for C56H73BrN9O13P2 439.07892 [M – 4 Na + 3 H]-, found 439.07911 [M – 
4 Na + 3 H]-. 
 
Sodium salt of {[(2-((8-bromoguanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (41) 
From compound 35 (177 mg, 0.27 mmol) according to Method E, afforded 56 mg (33%) of 
41 as white lyophilisate. 
1H NMR (D2O): 4.15 [d, 2H, J(1’,2’) = 7.5 Hz, H-1’]; 
3.53-3.68 [m, 8H, H-3’, H-4’]; 2.58 [m, 1H, H-2’]; 1.80-
1.91 [m, 4H, H-5’]. 13C NMR (D2O): 158.35 [C-6]; 154.30 
[C-2]; 153.70 [C-4]; 125.71 [C-8]; 116.84 [C-5]; 70.0 [C-
3’]; 67.09 [C-4’]; 45.08 [C-1’]; 38.78 [C-2’]; 29.31 [d, 
J(C,P) = 129.9 Hz, C-5’]. HR-MS (ESI-) m/z: calcd for 
C13H18BrN5Na4O9P2 532.00034 [M – 4 Na + 3 H]-, found 
532.00030 [M – 4 Na + 3 H]-. 
 
Sodium salt of {[(2-((8-bromohypoxanthine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (42) 
From compound 36 (248 mg, 0.39 mmol) according to Method E, afforded 42 mg (18%) of 
42 as white lyophilisate. 
1H NMR (D2O): 8.20 [s, 1H, H-2]; 4.37 [d, 2H, J(1’,2’) = 7.4 
Hz, H-1’]; 3.53-3.65 [m, 8H, H-3’, H-4’]; 2.63 [m, 1H, H-2’]; 
1.74-1.89 [m, 4H, H-5’]. 13C NMR (D2O): 157.93 [C-6]; 
151.16 [C-4]; 146.60 [C-2]; 129.34 [C-8]; 124.27 [C-5]; 
70.06 [C-3’]; 67.18 [C-4’]; 45.97 [C-1’]; 39.02 [C-2’]; 29.29 
[J(5’,P) = 130.0 Hz, C-5’]. HR-MS (ESI-) m/z: calcd for 
C13H17BrN4Na4O9P2 516.98944 [M – 4 Na + 3 H]+, found 
516.98971 [M – 4 Na + 3 H]+. 
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Sodium salt of {[(2-((7-deazaguanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (43) 
From compound 37 (400 mg, 0.7 mmol) according to Method E, afforded 56 mg (18%) of 43 
as white lyophilisate. 
1H NMR (D2O): 6.85 [d, 1H, J(8,7) = 3.6 Hz, H-8]; 6.47 
[d, 1H, J(7,8) = 3.6 Hz, H-7]; 4.08 [d, 2H, J(1’,2’) = 7.0 
Hz, H-1’]; 3.59-3.67 [m, 4H, CH2CH2-P]; 3.46 [d, 4H, 
J(3’,2’) = 5.9 Hz, H-3’]; 2.43 [m, 1H, H-2’]; 1.86-1.93 [m, 
4H, CH2-P]. 13C NMR (D2O): 162.04 [C-6]; 152.80 [C-2]; 
151.51 [C-4]; 124.19 [C-8]; 101.49 [C-7]; 100.44 [C-5]; 
69.58 [C-3’]; 67.14 [CH2CH2-P]; 44.31 [C-1’]; 40.13 [C-
2’]; 29.36 [d, J(C,P) = 130.0 Hz, CH2-P]. HR-MS (ESI-) m/z: calcd for 
C14H20N4Na4O9P2 453.09457 [M – 4 Na + 3 H]-, found 453.09416 [M – 4 Na + 3 H]-. 
 
Sodium salt of {[(2-((7-deazahypoxanthine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (44) 
From compound 38 (550 mg, 1 mmol) according to Method E, afforded 87 mg (17%) of 44 
as white lyophilisate. 
1H NMR (D2O): 8.05 [s, 1H, H-2]; 7.18 [d, 1H, J(8,7) = 3.5 
Hz, H-8]; 6.67 [d, 1H, J(7,8) = 3.5 Hz, H-7]; 4.27 [d, 2H, 
J(1’,2’) = 7.0 Hz, H-1’]; 3.56-3.64 [m, 4H, CH2CH2-P]; 3.47 
[d, 4H, J(3’,2’) = 5.8 Hz, H-3’]; 2.46 [m, H, H-2’]; 1.82-1.90 
[m, 4H, CH2-P]. 13C NMR (D2O): 161.43 [C-6]; 148.52 [C-
4]; 143.49 [C-2]; 127.01 [C-8]; 108.05 [C-5]; 102.09 [C-7]; 
69.60 [C-3’]; 67.2 [CH2CH2-P]; 45.01 [C-1’]; 40.39 [C-2’]; 
29.34 [d, J(C,P) = 129.5 Hz, CH2-P]. HR-MS (ESI-) m/z: calcd for 
C14H19N3Na4O9P2 504.02951 [M – Na]-, found 504.02909 [M – Na]-. 
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Tetraisopropyl {[(2-((8-bromoguanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(methylene)}bis(phosphonate) (45) 
From compound 1 (891 mg, 1.71 mmol) according to Method F, afforded 1.12 g (86%) of 45 
as yellowish-orange oil. Presence of product was confirmed by LC-MS (Procedure 1). Pure 
product was used in the next reaction step without additional characterisation. 
MS (ESI+) m/z = 674.2 [M + H]+. 
 
{[(2-((8-Bromoguanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(methylene)}diphosphonic acid (46) 
From compound 45 (1.07 g, 1.59 mmol) according to Method E, afforded 86 mg (11%) of 46 
as white lyophilisate. 
1H NMR (DMSO-d6:D2O, 1:1): 3.97 [d, 2H, J(1’, 2’) = 7.5 
Hz, H-1’]; 3.40-3.50 [m, 4H, H-3’]; 3.41 [dd, 2H, J(gem) = 
13.5 Hz, J(4’b,P) = 7.9 Hz, H-4’b]; 3.33 [dd, 2H, J(gem) = 
13.5 Hz, J(4’a,P) = 7.9 Hz, H-4’a]; 2.27 [m, 1H, H-2’]. 13C 
NMR (DMSO-d6:D2O, 1:1): 158.36 [C-6]; 155.12 [C-2]; 
154.32 [C-4]; 125.44 [C-8]; 117.69 [C-5]; 71.30 [d, J(C,P) = 
8.6 Hz, C-3’]; 68.67 [d, J(C,P) = 156.1 Hz, C-4’]; 44.51 [C-1’]; 40.59 [C-2’]. HR-MS (ESI+) 
m/z: calcd for C11H14BrN5Na4O9P2 503.96904 [M – 4 Na + 3 H]-, found 503.96882 [M – 4 Na 
+ 3 H]-. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-(guanine-9-yl)propane-1,3-
diyl)bis(oxy)]bis(ethane-2,1-diyl)}diphosphonic acid (47) 
From compound 12 (426 mg, 0.77 mmol) according to Method G, afforded 72 mg (8%) of 47 
as white lyophilisate. 
1H NMR (DMSO-d6): 10.58 [bs, 1H, H-1]; 
7.64 [s, 1H, H-8]; 7.10-7.29 [m, 20H, H-2’’, 
H-3’’, H-4’’]; 6.42 [bs, 2H, NH2]; 4.42-4.51 
[m, 3H, H-1’, 2x NH]; 3.92-4.07 [m, 12H, 
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CH2CH3, 2x NH, 2x NH-CH]; 3.79-3.86 [m, 2H, 2x NH-CH] 3.61-3.65 and 3.47-3.53 [m, 4H, 
H-2’]; 3.20-3.29 [m, 4H, CH2CH2-P]; 2.67-2.90 [m, 8H, 1’’-CH2]; 1.42-1.56 [m, 4H, CH2-P]; 
1.11, 1.11 and 1.05 [t, 12H, J(CH3,CH2) = 7.1 Hz, CH3]. 13C NMR (DMSO-d6): 173.12-
173.29 [m, COO]; 157.05 [C-6]; 153.60 [C-2]; 151.43 [C-4]; 137.44-137.50 [m, C-1’’]; 
129.63 and 129.59 [C-2’’]; 128.33 and 128.29 [C-3’’]; 126.62, 126.64, 126.70 and 126.71 [C-
4’’]; 68.65 [C-2’]; 65.44 [CH2CH2-P]; 60.58 and 60.46 [CH2CH3]; 54.03-54.43 [m, NH-CH]; 
53.48 [C-1’]; 40.09 [1’’-CH2]; 29.41-30.31 [m, CH2-P]; 14.14 and 14.07 [CH3]. HR-MS 
(ESI+) m/z: calcd for C56H73N9O13P2 1164.46953 [M + Na]+, found 1164.46958 [M + Na]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-(hypoxanthine-9-yl)propane-1,3-
diyl)bis(oxy)]bis(ethane-2,1-diyl)}diphosphonic acid (48) 
From compound 13 (536 mg, 1 mmol) according to Method G, afforded 376 mg (34%) of 48 
as yellowish lyophilisate. 
1H NMR (DMSO-d6): 12.30 [bs, 1H, H-1]; 
8.04 [s, 1H, H-8]; 8.03 [s, 1H, H-2]; 7.09-
7.27 [m, 20H, H-2’’, H-3’’, H-4’’]; 4.68 [m, 
1H, H-1’]; 4.43-4.49 [m, 2H, P-NH]; 3.91-
4.05 [m, 12H, CH2CH3, 2x P-NH, 2x NH-
CH]; 3.79-3.86 [m, 2H, NH-CH]; 3.72 and 
3.58 [m, 4H, H-2’]; 3.20-3.32 [m, 4H, H-3’]; 
2.67-2.90 [m, 8H, 1’’-CH2]; 1.39-1.56 [m, 4H, H-4’]; 1.03-1.13 [m, 12H, CH3]. 13C NMR 
(DMSO-d6): 173.07-173.24 [m, COO]; 156.89 [C-6]; 148.64 [C-4]; 145.52 [C-2]; 139.53 [C-
8]; 137.42-137.48 [m, C-1’’]; 129.59 and 129.55 [C-2’’]; 128.29 and 128.24 [C-3’’]; 126.66 
and 126.58 [C-4’’]; 124.05 [C-5]; 68.65 and 68.62 [C-2’]; 65.45 [C-3’]; 60.54 and 60.42 
[CH2CH3]; 54.44 [C-1’]; 54.36 and 54.00 [NH-CH]; 40.4 [1’’-CH2]; 29.36-30.28 [m, C-4’]; 
14.11 and 14.03 [CH3]. HR-MS (ESI+): calcd for C56H72N8O13P2 1149.45863 [M + Na]+, 
found 1149.45863 [M + Na]+. 
 
Tetra-(ʟ-Phenylalanine ethylester) prodrug of {[(2-(7-deazaguanine-9-yl)propane-1,3-
diyl)bis(oxy)]bis(ethane-2,1-diyl)}diphosphonic acid (49) 
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From compound 16 (213 mg, 0.39 mmol) according to Method G, afforded 212 mg (48%) of 
49 as yellowish lyophilisate. 
1H NMR (DMSO-d6): 10.30 [bs, 1H, H-1]; 
7.09-7.28 [m, 20H, H-2’’, H-3’’, H-4’’]; 6.73 
[d, 1H, J(8,7) = 3.6 Hz, H-8]; 6.23 [d, 1H, 
J(7,8) = 3.6 Hz, H-7]; 6.17 [bs, 2H, NH2]; 
4.61 [m, 1H, H-1’]; 4.43-4.49 [m, 2H, P-
NH]; 3.91-4.04 [m, 12H, CH2CH3, 2x P-NH, 
2x NH-CH]; 3.79-3.86 [m, 2H, NH-CH]; 
3.45-3.56 [m, 4H, H-2’]; 3.19-3.31 [m, 4H, CH2CH2-P]; 2.67-2.90 [m, 8H, 1’’-CH2]; 1.43-
1.59 [m, 4H, CH2-P]; 1.04-1.13 [m, 12H, CH3]. 13C NMR (DMSO-d6): 173.08-173.24 [m, 
COO]; 158.87 [C-6]; 152.40 [C-2]; 150.57 [C-4]; 137.47, 137.46, 137.43 and 137.41 [C-1’’]; 
129.59 and 129.54 [C-2’’]; 128.29 and 128.26 [C-3’’]; 126.67 and 126.61 [C-4’’]; 118.35 [C-
8]; 101.39 [C-7]; 99.98 [C-5]; 69.32 [C-2’]; 65.37 [d, J(C,C,P) = 3.1 Hz, CH2CH2-P]; 60.54 
and 60.42 [CH2CH3]; 54.40 [d, J(C,N,P) = 3.7 Hz, NH-CH]; 54.01 [d, J(C,N,P) = 3.3 Hz, 
NH-CH]; 52.95 [C-1’]; 39.8 [1’’-CH2]; 29.87 [d, J(C,P) = 112.0 Hz, CH2-P]; 14.11 and 14.04 
[CH3]. HR-MS (ESI+) m/z: calcd for C57H74N8O13P2 1163.47428 [M + Na]+, found 
1163.47434 [M + Na]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-(7-deazahypoxanthine-9-yl)propane-
1,3-diyl)bis(oxy)]bis(ethane-2,1-diyl)}diphosphonic acid (50) 
From compound 17 (400 mg, 0.74 mmol) according to Method G, afforded 284 mg (34%) of 
50 as white lyophilisate. 
1H NMR (DMSO-d6): 11.90 [bs, 1H, H-1]; 
7.87 [s, 1H, H-2]; 7.08-7.28 [m, 21H, H-8, H-
2’’, H-3’’, H-4’’]; 6.48 [d, 1H, J(7,8) = 3.5 
Hz, H-7]; 4.83 [m, 1H, H-1’]; 4.44-4.50 [m, 
2H, NH-P]; 3.92-4.04 [m, 12H, CH2CH3, 2x 
NH-P, 2x NH-CH]; 3.78-3.85 [m, 2H, NH-
CH]; 3.62 and 3.53 [m, 4H, H-2’]; 3.18-3.30 
[m, 4H, CH2CH2-P]; 2.66-2.89 [m, 8H, 1’’-CH2]; 1.38-1.55 [m, 4H, CH2-P]; 1.03-1.13 [m, 
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12H, CH3]. 13C NMR (DMSO-d6): 173.11-173.29 [m, COO]; 158.49 [C-6]; 147.57 [C-4]; 
143.39 [C-2]; 137.45-137.51 [m, C-1’’]; 129.63 and 129.58 [C-2’’]; 128.33 and 128.29 [C-
3’’]; 126.71 and 126.63 [C-4’’]; 122.17 [C-8]; 107.96 [C-5]; 101.75 [C-7]; 69.38 [C-2’]; 
65.43 [CH2CH2-P]; 60.57 and 60.45 [CH2CH3]; 53.91-54.42 [m, C-1’, NH-CH]; 39.8 [1’’-
CH2]; 29.86 [d, J(C,P) = 111.9 Hz, CH2-P]; 14.16 and 14.08 [CH3]. HR-MS (ESI+) m/z: calcd 
for C57H73N7O13P2 1126.48143 [M + H]+, found 1126.48196 [M + H]+. 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-((guanine-9-yl)methyl)propane-1,3-
diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (51) 
From compound 33 (554 mg, 0.98 mmol) according to Method G, afforded 539 mg (48 %) of 
51 as white lyophilisate. 
1H NMR (DMSO-d6): 10.52 [bs, 1H, NH]; 7.51 [s, 
1H, H-8]; 7.10-7.28 [m, 20H, H-2’’, H-3’’, H-4’’]; 
6.52 [bs, 2H, NH2]; 4.47-4.54 [m, 2H, P-NH]; 3.79-
4.14 [m, 16H, 2x P-NH, H-1’, CH2CH3, 4xNH-CH]; 
3.18-3.28 [m, 4H, H-4’]; 3.07-3.12 [m, 4H, H-3’]; 
2.71-2.94 [m, 8H, 1’’-CH2]; 2.14 [m, 1H, H-2’]; 
1.50-1.63 [m, 4H, H-5’]; 1.04-1.14 [m, 12H, 
CH2CH3]. 13C NMR (DMSO-d6): 173.03-173.29 [m, 
COO]; 157.01 [C-6]; 153.71 [C-2]; 151.66 [C-4]; 
138.13 [C-8]; 137.47, 137.43, 137.39 and 137.36 [C-1’’]; 129.61 and 129.57 [C-2’’]; 128.31 
and 128.25 [C-3’’]; 126.69 and 126.59 [C-4’’]; 116.60 [C-5]; 68.32 [C-3’]; 65.13 and 65.04 
[C-4’]; 60.57 and 60.46 [CH2CH3]; 54.02-54.11 [m, NH-CH]; 41.40 [C-1’]; 40.2 [1’’-CH2]; 
39.3 [C-2’]; 30.09 [d, J(C,P) = 113.0 Hz, C-5’]; 14.13 and 14.05 and 14.05 [CH2CH3]. HR-
MS (ESI+) m/z: calcd for C57H75N9O13P2 1178.48518 [M + Na]+, found 1178.48562 [M + 
Na]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-((hypoxanthine-9-yl)methyl)propane-
1,3-diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (52) 
From compound 34 (313 mg, 0.57 mmol) according to Method G, afforded 288 mg (44%) of 
52 as white lyophilisate. 
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1H NMR (DMSO-d6): 12.29 [bs, 1H, NH]; 8.01 [s, 1H, 
H-2]; 7.89 [s, 1H, H-8]; 7.11-7.27 [m, 20H, H-2’’, H-
3’’, H-4’’); 4.42-4.49 [m, 2H, P-NH]; 3.94-4.08 [m, 
14H, 2x P-NH, H-1’, CH2CH3, 2x NH-CH]; 3.82-3.89 
[m, 2H, NH-CH]; 3.16-3.28 [m, 4H, H-4’]; 3.07-3.14 
[m, 4H, H-3’]; 2.70-2.93 [m, 8H, 1’’-CH2]; 2.19 [m, 
1H, H-2’]; 1.47-1.57 [m, 4H, H-5’]; 1.05-1.14 [m, 12H, 
CH2CH3]. 13C NMR (DMSO-d6): 173.07-173.29 [m, 
COO]; 157.51 [C-6]; 148.86 [C-4]; 146.12 [C-2]; 
140.71 [C-8]; 137.47, 137.45, 137.41 and 137.38 [C-1’’]; 129.60 and 129.59 [C-2’’]; 128.29 
and 128.24 [C-3’’]; 126.67 and 126.59 [C-4’’]; 124.06 [C-5]; 68.48 [C-3’]; 65.31 [C-2’]; 
60.58 and 60.46 [CH2CH3]; 53.99-54.37 [m, NH-CH]; 42.42 [C-1’]; 39.8 [1’’-CH2]; 39.2 [C-
2’]; 29.99 [d, J(C,P) = 112.9 Hz, C-5’]; 14.13, 14.07 and 14.06 [CH2CH3]. HR-MS (ESI+) 
m/z: calcd for C57H74N8O13P2 1163.47428 [M + Na]+, found 1163.47447 [M + Na]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-((7-deazaguanine-9-
yl)methyl)propane-1,3-diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (53) 
From compound 37 (369 g, 0.65 mmol) according to Method G, afforded 331 mg (44%) of 
53 as white lyophilisate. 
1H NMR (DMSO-d6): 10.28 [bs, 1H, H-1]; 7.09-
7.28 [m, 20H, H-2’’, H-3’’, H-4’’]; 6.57 [d, 1H, 
J(8,7) = 3.4 Hz, H-8]; 6.33 [bs, 2H, NH2]; 6.22 [d, 
1H, J(7,8) = 3.4 Hz, H-7]; 4.49-4.56 and 4.08-4.14 
[m, 4H, NH]; 3.93-4.04 [m, 10H, CH2CH3, 2x NH-
CH]; 3.80-3.88 [m, 4H, H-1’, 2x NH-CH]; 3.16-3.39 
[m, 4H, CH2CH2-P]; 3.06-3.12 [m, 4H, H-3’]; 2.70-
2.93 [m, 8H, 1’’-CH2]; 2.12 [m, 1H, H-2’]; 1.49-
1.63 [m, 4H, CH2-P]; 1.04-1.13 [m, 12H, CH3]. 13C 
NMR (DMSO-d6): 173.05-173.34 [m, COO]; 158.92 [C-6]; 152.57 [C-2]; 150.69 [C-4]; 
137.52, 137.48, 137.42 and 137.38 [C-1’’]; 129.65 and 129.60 [C-2’’]; 128.35 and 128.29 [C-
3’’]; 126.73 and 126.65 [C-4’’]; 121.00 [C-8]; 101.22 [C-7]; 99.95 [C-5]; 68.53-68.51 [C-3’]; 
65.13 and 65.04 [CH2CH2-P]; 60.61 and 60.50 [CH2CH3]; 54.06-54.45 [m, NH-CH]; 42.74 
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[C-1’]; 39.9 [1’’-CH2]; 39.5 [C-2’]; 30.13 [d, J(C,P) = 112.5 Hz, CH2-P]; 14.09-14.17 [m, 
CH3]. HR-MS (ESI+) m/z: calcd for C58H76N8O13P2 1177.48993 [M + Na]+, found 
1177.49038 [M + Na]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-((7-deazahypoxanthine-9-
yl)methyl)propane-1,3-diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (54) 
From compound 38 (550 mg, 1 mmol) according to Method G, afforded 311 mg (27%) of 54 
as white lyophilisate. 
1H NMR (DMSO-d6): 11.89 [bs, 1H, H-1]; 7.88 [s, 1H, 
H-2]; 7.10-7.27 [m, 20H, H-2’’, H-3’’, H-4’’]; 6.99 [d, 
1H, J(8,7) = 3.4 Hz, H-8]; 6.47 [d, J(7,8) = 3.4 Hz, H-
7]; 4.42-4.48 [m, 2H, NH-P]; 3.94-4.07 [m, 14H, 2x 
NH-P, H-1’, 2x NH-CH, CH2CH3]; 3.82-3.89 [m, 2H, 
2x NH-CH]; 3.15-3.28 [m, 4H, CH2CH2-P]; 3.05-3.14 
[m, 4H, H-3’]; 2.70-2.93 [m, 8H, 1’’-CH2]; 2.17 [m, 
1H, H-2’]; 1.47-1.60 [m, 4H, CH2-P]; 1.05-1.14 [m, 
12H, CH3]. 13C NMR (DMSO-d6): 173.04-173.25 [m, 
COO]; 158.44 [C-6]; 147.48 [C-4]; 143.46 [C-2]; 137.46, 137.44, 137.39 and 137.36 [C-1’’]; 
129.59 and 129.57 [C-2’’]; 128.28 and 128.23 [C-3’’]; 126.66 and 126.58 [C-4’’]; 124.47 [C-
8]; 107.89 [C-5]; 101.53 [C-7]; 68.57 [C-3’]; 65.29 [CH2CH2-P]; 60.56 and 60.45 [CH2CH3]; 
54.00-54.36 [m, NH-CH]; 43.59 [C-1’]; 39.9 [1’’-CH2]; 39.9 [C-2’]; 30.03 [d, J(C,P) = 112.3 
Hz, CH2-P]; 14.04-14.12 [m, CH3]. HR-MS (ESI+) m/z: calcd for C58H75N7O13P2 1162.47903 
[M + Na]+, found 1162.47956 [M + Na]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-(8-bromoguanine-9-yl)propane-1,3-
diyl)bis(oxy)]bis(ethane-2,1-diyl)}diphosphonic acid (55)  
From compound 47 (300 mg, 0.47 mmol) according to Method H, afforded 380 mg (66%) of 
55 as yellowish lyophilisate. 
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1H NMR (DMSO-d6): 10.64 [bs, 1H, H-1]; 
7.10-7.28 [m, 20H, H-2’’, H-3’’, H-4’’]; 6.38 
[bs, 2H, NH2]; 4.60 [m, 1H, H-1’]; 4.15-4.21 
[m, 2H, P-NH]; 3.83-4.06 [m, 16H, CH2CH3, 
2x P-NH, NH-CH, H-2’a]; 3.63.3.67 [m, 2H, 
2’b]; 3.26-3.42 [m, 4H, CH2CH2-P]; 2.72-
2.93 [m, 8H, 1’’-CH2]; 1.51-1.64 [m, 4H, 
CH2-P]; 1.07-1.14 [m, 12H, CH3]. 13C NMR (DMSO-d6): 172.61-172.73 [m, COO]; 155.46 
[C-6]; 153.19 [C-2]; 152.31 [C-4]; 137.14 and 137.11 [C-1’’]; 129.17-129.20 [m, C-2’’]; 
127.90-127.93 [m, C-3’’]; 126.26-126.31 [m, C-4’’]; 117.32 [C-5]; 67.27 [C-2’]; 65.14 
[CH2CH2-P]; 60.19, 60.18, 60.11 and 60.09 [CH2CH3]; 57.14 [H-1’]; 53.82-54.05 [m, NH-
CH]; 39.92 [1’’-CH2]; 29.88 [d, J(C,P) = 112.1 Hz, CH2-P]; 13.74-13.69 [CH3]. HR-MS 
(ESI+) m/z: calcd for C56H72BrN9O13P2 1220.39810 [M + H]+, found 1220.39854 [M + H]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-(8-bromohypoxanthine-9-yl)propane-
1,3-diyl)bis(oxy)]bis(ethane-2,1-diyl)}diphosphonic acid (56) 
From compound 48 (170 mg, 0.15 mmol) according to Method H, afforded 23 mg (13%) of 
56 as white lyophilisate. 
1H NMR (DMSO-d6): 12.54 [bs, 1H, H-1]; 
8.06 [s, 1H, H-2]; 7.08-7.27 [m, 20H, H-2’’, 
H-3’’, H-4’’]; 4.68 [m, 1H, H-1’]; 4.43-4.54 
[m, 2H, NH]; 3.89-4.05 [m, 14H, CH2CH3, 
H-2’a, NH, 2x NH-CH]; 3.76-3.83 [m, 2H, 
NH-CH]; 3.61-3.66 [m, 2H, H-2’b]; 3.15-
3.35 [m, 4H, CH2CH2-P]; 2.63-2.89 [m, 8H, 
1’’-CH2]; 1.34-1.51 [m, 4H, CH2-P]; 1.02-1.13 [m, 12H, CH3]. 13C NMR (DMSO-d6): 
173.15-173.30 [m, COO]; 155.62 [C-6]; 149.71 [C-4]; 145.91 [C-2]; 137.49-137.52 [m, C-
1’’]; 129.61-129.66 [m, C-2’’]; 128.30-128.37 [m, C-3’’]; 126.66-126.75 [m, C-4’’]; 125.20 
[C-8]; 124.08 [C-5]; 67.33 and 67.24 [C-2’]; 65.44 [CH2CH2-P]; 60.47-60.62 [CH2CH3]; 58.8 
[C-1’]; 53.99-54.44 [m, NH-CH]; 39.8 [1’’-CH2]; 29.35-30.29 [m, CH2-P]; 14.19, 14.18 and 
14.10 [CH2CH3]. HR-MS (ESI+) m/z: calcd for C56H71BrN8O13P2 1227.36914 [M + Na]+, 
found 1227.36943 [M + Na]+. 
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Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-((8-bromoguanine-9-
yl)methyl)propane-1,3-diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (57) 
From compound 51 (175 mg, 0.15 mmol) according to Method H, afforded 32 mg (17%) of 
57 as white lyophilisate. 
1H NMR (DMSO-d6): 10.65 [bs, 1H, H-1]; 7.08-
7.28 [m, 20H, H-2’’, H-3’’, H-4’’]; 6.75 [bs, 2H, 
NH2]; 4.46-4.56 [m, 2H, NH]; 3.81-4.12 [m, 16H, 
2x NH, H-1’, CH2CH3, NH-CH]; 3.12-3.40 [m, 8H, 
H-4’, H-3’]; 2.69-2.93 [m, 8H, 1’’-CH2]; 2.24 [m, 
1H, H-2’]; 1.51-1.62 [m, 4H,  H-5’]; 1.03-1.14 [m, 
12H, CH2CH3]. 13C NMR (DMSO-d6): 172.97-
173.29 [m, COO]; 155.80 [C-6]; 154.05 [C-2]; 
152.93 [C-4]; 137.50, 137.44, 137.40 and 137.35 
[C-1’’]; 129.60, 129.59 and 129.53 [C-2’’]; 128.31, 128.26 and 128.23 [C-3’’]; 126.69, 
126.61 and 126.57 [C-4’’]; 121.30 [C-8]; 116.86 [C-5]; 68.39-68.50 [m, C-3’]; 60.05 and 
64.91 [C-4’]; 60.58, 60.55, 60.48 and 60.43 [CH2CH3]; 53.96-54.47 [m, NH-CH]; 42.67 [C-
1’]; 40.2 [1’’-CH2]; 38.82 [C-2’]; 29.60-30.54 [m, C-5’]; 14.13, 14.11, 14.07 and 14.02 
[CH2CH3]. HR-MS (ESI+) m/z: calcd for C57H74BrN9O13P2 1234.41375 [M + H]+, found 
1234.41473 [M + H]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-((8-bromohypoxanthine-9-
yl)methyl)propane-1,3-diyl)bis(oxy)]bis(ethylene)}diphosphonic acid (58) 
From compound 52 (113 mg, 0.1 mmol) according to Method H, afforded 26 mg (21%) of 58 
as white lyophilisate. 
1H NMR (DMSO-d6): 12.48 [d, 1H, J(1,2) = 3.6 Hz, H-
1]; 8.06 [d, 1H, J(2,1) = 3.6 Hz, H-2]; 7.10-7.28 [m, 
20H, H-2’’, H-3’’, H-4’’]; 4.42-4.46 [m, 2H, NH]; 
3.92-4.08 [m, 14H, 2x NH, H-1’, CH2CH3, 2x NH-
CH]; 3.80-3.87 [m, 2H, NH-CH]; 3.11-3.26 [m, 8H, H-
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4’, H-3’]; 2.68-2.92 [m, 8H, 1’’-CH2]; 2.31 [m, 1H, H-2’]; 1.43-1.57 [m, 4H, H-5’]; 1.04-1.14 
[m, 12H, CH2CH3]. 13C NMR (DMSO-d6): 173.05-173.25 [m, COO]; 155.54 [C-6]; 150.19 
[C-4]; 146.31 [C-2]; 137.46, 137.45, 137.41 and 137.41 [C-1’’]; 129.61 and 129.57 [C-2’’]; 
128.29, 128.28, 128.25 and 128.24 [C-3’’]; 126.67, 126.65, 126.59 and 126.58 [C-4’’]; 
125.86 [C-8]; 124.42 [C-5]; 68.68 and 68.65 [C-3’]; 65.32 [C-4’]; 60.56, 60.55, 60.46 and 
60.45 [CH2CH3]; 53.97-54.37 [m, NH-CH]; 44.16 [C-1’]; 40.2 [1’’-CH2]; 39.2 [C-2’] ; 29.48-
30.39 [m, C-5’]; 14.14, 14.13, 14.07 and 14.06 [CH2CH3]. HR-MS (ESI+) m/z: calcd for 
C57H73BrN8O13P2 1241.38479 [M + Na]+, found 1241.38494 [M + Na]+. 
 
Tetra-(ʟ-phenylalanine ethylester) prodrug of {[(2-((8-bromoguanine-9-
yl)methyl)propane-1,3-diyl)bis(oxy)]bis(methylene)}diphosphonic acid (60) 
From compound 59 (180 mg, 0.16 mmol) according to Method H, afforded 23 mg (12%) of 
60 as white lyophilisate. 
1H NMR (DMSO-d6): 10.76 [bs, 1H, H-1]; 7.11-
7.25 [m, 20H, H-2’’, H-3’’, H-4’’]; 6.62 [bs, 2H, 
NH2]; 4.40-4.52 and 4.15-4.21 [m, 4H, NH]; 3.81-
4.05 [m, 10H, CH2CH3, H-1’]; 3.02-3.33 [m, 8H, H-
3’, CH2-P]; 2.74-2.94 [m, 8H, 1’’-CH2]; 2.23 [m, 
1H, H-2’]; 1.02-1.13 [m, 12H, CH3]. 13C NMR 
(DMSO-d6): 172.78-173.08 [m, COO]; 155.83 and 
154.13 [C-2, C-6]; 152.84 [C-4]; 137.17-137.39 [m, 
C-1’’]; 129.67 [C-2’’]; 128.29-128.33 [m, C-3’’]; 
126.66-126.74 [m, C-4’’]; 121.12 [C-8]; 116.95 [C-5]; 70.43-70.71 [m, C-3’]; 67.76 [d, 
J(C,P) = 136.2 Hz, CH2-P]; 60.60-60.72 [m, CH2CH3]; 53.87-54.19 [m, NH-CH]; 42.38 [C-
1’]; 39.8 [1’’-CH2]; 39.09 [C-2’]; 14.07-14.17 [m, CH3]. HR-MS (ESI+): calcd for 
C55H70BrN9O13P2 1206.38245 [M + H]+, found 1206.38309 [M + H]+. 
 
Biological assays 
Determination of Ki values 
The Ki values for the human, Pf and Pv enzymes were determined as previously described.19 
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The Ki values were measured using a spectrophotometric assay at 25oC in triplicate. All 
assays were performed in 0.1 M Tris-HCl, 10 mM MgCl2 at pH 7.4. All of the Ki values were 
subsequently calculated using the equations v = Vmax . [S]o/[S]o + Km(app) and Km(app) = Km (1+ 
[I]/Ki(app)). 
 
In vitro antimalarial activity of ANbP prodrugs 
P. falciparum D6 (Sierra-Leone) laboratory line, sensitive to most antimalarial drugs and W2 
(Indochina) line, resistant to chloroquine and pyrimethamine, were maintained as previously 
described41 in RPMI-1640-LPLF complete medium, containing 10.4 g/L RPMI-1640-LPLF 
powder (Gibco BRL), 5.97 g/L HEPES buffer (MP Biomedicals, USA), 2.0 g/L D-glucose 
(BDH chemicals, Australia), 0.05 g/L hypoxanthine (Sigma, USA) and 40 mg/L gentamycin 
(Pfizer, Australia) with pH adjusted to 6.9. The sodium bicarbonate solution (0.21% final 
concentration) and human plasma (10% final) were added prior to use. Cultures were 
maintained at 4% haematocrit (O(+) RBC) and 1% to 8% parasitaemia at 37ºC in a special 
gas mixture (5% O2, 5% CO2 and 90% N2). Cultures were routinely synchronised using D-
sorbitol.42 The antimalarial activity of the ANPs was evaluated using the [3H]-hypoxanthine 
growth inhibition assay.43 For these assays, stock solutions of ANPs were made to 
concentrations of 20-40 mM in DMSO or water and subsequently diluted in hypoxanthine-
free complete media prior to assay. The assays (in 96-well plate format) were initiated when 
the majority of parasites (>90%) at early trophozoite (ring) stage. Parasite cultures (100 µL 
per well) at 0.5% initial parasitemia and 2% hematocrit in hypoxanthine-free RPMI1640-
LPLF medium were exposed to ten 2-fold serial dilutions of the ANPs and chloroquine (CQ) 
(reference drug) for 96 hours, with [3H]-hypoxanthine (0.2 µCi/well) added ~48 hours after 
beginning of the experiment. The [3H]-hypoxanthine incorporation data were analyzed and 
sigmoidal growth inhibition curves were produced by non-linear regression analysis of the 
[3H]-hypoxanthine incorporation data versus log-transformed concentrations of the 
compounds using Graphpad Prism V5.0 software (GraphPad Software Inc. USA), from which 
the inhibitory concentration (IC50) that cause 50% of parasite growth were determined. The 
IC50 values were based on at least two independent experiments with mean (±SD) calculated. 
 
Cytotoxicity assays in human cell lines 
Human lung carcinoma A549 cells were seeded in 96-well plates at 7500 cells per well, and 
on the next day the compounds were added in serial dilutions. After four days incubation at 
37°C, the cells were trypsinized, then counted with a Coulter Counter apparatus. The CC50 or 
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50% cytostatic concentration, defined as the compound concentration producing 50% 
inhibition of cell proliferation as compared to the no compound control, was calculated by 
extrapolation assuming a semi-log dose-response effect. 
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